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HUMAN GENE-EDITING RESEARCH: IS THE 
FUTURE HERE YET?* 
NANCY M. P. KING** 
Since the discovery of DNA, researchers have pursued the 
prospect of correcting genetic disorders using genetic 
interventions. The most recent development, gene editing, poses 
many scientific, medical, ethical, and policy challenges, especially 
when the goal is editing the genomes of embryos, creating 
changes that can be inherited by future generations. Genetic 
treatments for already-born persons are not controversial, but 
inheritable genetic changes raise concerns about dangerous 
outcomes, questions about how to prioritize among scientific and 
societal needs, and worries about pursuing genetic changes that 
are enhancements rather than treatments for disease. The history 
of genetic-intervention research and the development of gene-
editing tools like CRISPR were complicated enough, even before 
the “CRISPR babies” controversy arose in late 2018. CRISPR 
and related editing technologies should be used for basic 
research in order to learn more about human development and 
disease, but there is considerable disagreement and reason to be 
cautious about clinical applications. Moreover, no global 
enforcement mechanism exists to detect and prevent deviations 
from policy. Improved transparency, robust ongoing discussion, 
and increased education in ethics and genetics for scientists, 
students, and the public may therefore be both achievable goals 
and best practices for this rapidly developing science. 
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INTRODUCTION 
Gene editing is the technical process of deleting segments of 
DNA from an organism’s genes, and sometimes substituting new 
DNA sequences, in order to eliminate deleterious mutations. 1 
Advances in gene-editing technology have renewed hopes of 
correcting genetic defects in humans and rekindled debates about the 
many ethical, social, and policy consequences of genetic 
manipulation, especially when changes will be passed on through the 
germline, that is, to future generations. Gene-editing tools like 
CRISPR-associated protein 9 (“CRISPR-Cas9”) are potentially 
precise, accurate, easy, quick, and cheap. As a result, gene editing has 
also renewed long-standing debates about efforts to pursue human 
 
 1. Nonscientists will welcome the accessibility, comprehensive history, and sweeping 
survey of ethical and policy issues raised by gene editing in a highly readable book by one 
of the discoverers of CRISPR. See generally JENNIFER A. DOUDNA & SAMUEL H. 
STERNBERG, A CRACK IN CREATION: GENE EDITING AND THE UNTHINKABLE POWER 
TO CONTROL EVOLUTION (2017). For a shorter and equally accessible overview, see 
Jennifer Kahn, The CRISPR Quandary, N.Y. TIMES MAG. (Nov. 9, 2015), 
https://www.nytimes.com/2015/11/15/magazine/the-crispr-quandary.html [https://perma.cc/
9YW3-BCVQ (dark archive)]. In addition, students of popular culture may appreciate two 
YouTube videos about CRISPR. See acapellascience, CRISPR-Cas9 (“Mr. Sandman” 
Parody) | A Capella Science, YOUTUBE (Oct. 8, 2016), https://www.youtube.com/
watch?v=k99bMtg4zRk [https://perma.cc/W9PK-PG39]; LastWeekTonight, Gene Editing: 
Last Week Tonight with John Oliver (HBO), YOUTUBE (July 1, 2018), 
https://www.youtube.com/watch?v=AJm8PeWkiEU [https://perma.cc/4C2M-DE6V]. 
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germline alteration and enhancement. These debates reached fever 
pitch in late November 2018, when Chinese scientist Dr. He Jiankui 
claimed to the world that he had accomplished genome editing of two 
zygotes successfully brought to term as twin girls.2 At first it was 
unclear whether the twins actually existed, but it became increasingly 
clear that Dr. He had lied, ignored ethics guidelines, and cut 
regulatory corners at best, and that the purported edits were probably 
ineffective and possibly dangerous.3 
This Article examines the new gene-editing boom, considering 
briefly a range of issues—namely, the safety, efficacy, affordability, 
ethical and social acceptability, oversight, and control of this novel 
biotechnology. Part I, a very basic introduction to the science of gene 
editing, notes the similarities and differences between gene editing 
and its predecessor, gene transfer or gene addition, and a potential 
successor, base editing. This part continues by examining the policy 
furor that followed the first publications reporting about gene-editing 
research efforts in human embryos. It concludes that keeping up with 
the science and managing its oversight have become significant 
challenges for policymakers and bioethics scholars. Part II considers 
the prospect of human gene editing in its social and historical context, 
examining the most recent scientific developments and the policy 
debates engendered thereby, including the recent, unexpected, and 
highly controversial reported birth of gene-edited twins in China. Part 
III then discusses ethical and policy debates and future prospects for 
ethical consensus on whether, where, when, and how to move forward 
with human gene-editing research and clinical translation applied to 
embryos intended for birth. This part addresses somatic versus 
germline editing and gene editing’s connection to and dependence on 
basic assisted reproduction technologies like in vitro fertilization 
 
 2. See infra notes 83–98 and accompanying text. 
 3. Dr. He’s claims were first brought to public attention in late November 2018. See 
Antonio Regalado, Exclusive: Chinese Scientists Are Creating CRISPR Babies, MIT TECH. 
REV. (Nov. 25, 2018), https://www.technologyreview.com/s/612458/exclusive-chinese-
scientists-are-creating-crispr-babies/ [https://perma.cc/9FLZ-3UJ4] [hereinafter Regalado, 
Chinese Scientists]. Also on November 25, Dr. He released a YouTube video about his 
claims. The He Lab, About Lulu and Nana: Twin Girls Born Healthy After Gene Surgery 
as Single-Cell Embryos, YOUTUBE (Nov. 25, 2018), https://www.youtube.com/
watch?v=th0vnOmFltc [https://perma.cc/H3XM-EE97]. For a summary of Dr. He’s claims 
and responses to those claims, see Sharon Begley & Andrew Joseph, The CRISPR 
Shocker: How Genome Editing Scientist He Jiankui Rose from Obscurity to Stun the 
World, STAT (Dec. 17, 2018), https://www.statnews.com/2018/12/17/crispr-shocker-
genome-editing-scientist-he-jiankui/ [https://perma.cc/ARU5-US4N]; see also infra notes 
86–98 and accompanying text. 
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(“IVF”) and preimplantation genetic diagnosis (“PGD”), including 
controversial arguments about the necessity of germline alteration. 
This part also addresses treatment versus enhancement and questions 
of governance and access. Part IV suggests the need to refocus 
emphasis on modeling and adhering to careful, meticulous, and 
responsible science, as taught and practiced in laboratories around 
the world, in both preclinical and translational research settings. 
Responsible science, fostered by good education in sound and ethical 
scientific practice, has the best chance—if there is any chance—of 
promoting the conduct of reason-grounded and thoughtful research, 
and of helping to ensure robust public discussion of and policy 
deliberation about ethically sound scientific progress. 
I.  THE SCIENCE AND EARLY HISTORY OF GENE EDITING 
Gene editing has captured the public imagination since CRISPR 
first hit the news just a few years ago.4 It is noteworthy, however, that 
most of the scientific, medical, ethical, and policy issues raised by 
gene editing echo questions and problems that have been discussed 
since Watson, Crick, and Franklin first identified the double helix.5 
This Article addresses some of the most significant implications of 
future human clinical applications of gene editing.6 
 
 4. See supra note 1. 
 5. Tracy Hampton, Ethical and Societal Questions Loom Large as Gene Editing 
Moves Closer to the Clinic, 315 JAMA 546, 546–48 (2016). The deoxyribonucleic acid 
(“DNA”) helix was identified in 1953. By the 1970s, the search for effective gene-based 
treatments for human genetic diseases had begun in earnest. Mary Carrington Coutts, 
Human Gene Therapy, 4 KENNEDY INST. ETHICS J. 63, 65 (1994) The first human patient-
subject, Ashanti de Silva, received a gene-transfer (now often referred to as gene 
augmentation) intervention in 1990. Id. at 63. In 1999, Jesse Gelsinger became the first 
patient-subject to die as a result of a gene-transfer research intervention. Rick Weiss & 
Deborah Nelson, Methods Faulted in Gene Test Death: Teen Too Ill for Therapy, Probe 
Finds, WASH. POST, Dec. 8, 1999, at A1; Paul Gelsinger, Jesse’s Intent, GUINEA PIG ZERO 
(2000), http://www.guineapigzero.com/jesses-intent.html [https://perma.cc/R5PG-8S3X]. 
The first gene-transfer intervention was approved as a therapy in 2004 in China. Sue 
Pearson, Hepeng Jia & Keiko Kandachi, China Approves First Gene Therapy, 22 NATURE 
BIOTECHNOLOGY 3, 3–4 (2004). A few more gene-transfer interventions have been 
approved to date as therapies by the European Medicines Agency (“EMA”), see Nuala 
Moran, First Gene Therapy Glybera (Finally) Gets EMA Approval, BIOWORLD (Nov. 2, 
2012), http://www.bioworld.com/content/first-gene-therapy-glybera-finally-gets-ema-approval-1 
[https://perma.cc/5BQN-U4FT], and the FDA, News Release, FDA, FDA Approves Novel 
Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss (Dec. 19, 
2017), https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm 
[https://perma.cc/LSH7-YNEN]. 
 6. This Article draws on some of my previous work on gene editing and related 
novel biotechnologies, most notably Nancy M. P. King, Pat C. Lord & Douglas E. Lemley, 
97 N.C. L. REV. 1051 (2019) 
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A. Science and Ethics in a Fast-Moving Field 
Researchers have been attempting to “edit” genes, by deleting 
harmful genes and replacing them in the genome with nonmutated 
versions, since the 1990s.7 The tools and techniques first used in gene 
editing, zinc finger nucleases (“ZFNs”) and transcription activator-
like effector nucleases (“TALENs”), are complex and difficult to 
master; their slow progress thus attracted little notice.8 But then came 
CRISPR (clustered regularly interspersed palindromic repeats), 
which was first discovered as an adaptive immune system in bacteria 
but was quickly modified to specifically target any DNA sequence.9 
Since mid-2014, the explosion of scientific, medical, and public 
 
Editing the Genome: Prospects, Progress, Implications, and Cautions, 5 CURRENT 
GENETIC MED. REP. 35, 35–43 (2017). It is unfortunately not possible, however, to 
address all or even most of the relevant issues without taking up excessive space and trying 
readers’ patience. Many significant ethical and policy issues arise from applications of 
gene editing (and gene drives) to plants and animals. These issues include not only 
agricultural and animal husbandry applications but also basement biohacking and the 
potential weaponization of genetically altered organisms. All this and more is well beyond 
the scope of this Article, yet others have given these topics expert treatment. See generally 
NAT’L ACADS. OF SCIS., ENG’G, & MED., GENE DRIVES ON THE HORIZON (2016) 
(summarizing the scientific discoveries related to gene drives and considerations for their 
responsible use); Sharon Begley, Monsanto Licenses CRISPR Technology to Modify 
Crops—with Key Restrictions, STAT (Sept. 22, 2016), https://www.statnews.com/2016/09/
22/monsanto-licenses-crispr/ [https://perma.cc/G3MS-FKG3]. Nor do I address the 
prospect of using gene editing and related technologies to create human-animal chimeras, 
such as “humanized” pigs capable of growing human organs suitable for transplantation, 
which raises issues that are related to but distinguishable from those addressed in this 
Article and that deserve thorough examination. See, e.g., David Shaw et al., Creating 
Human Organs in Chimaera Pigs: An Ethical Source of Immunocompatible Organs?, 41 J. 
MED. ETHICS 970, 970–74 (2015); Fergus Walsh, US Bid to Grow Human Organs for 
Transplant Inside Pigs, BBC NEWS (June 6, 2016), www.bbc.com/news/health-36437428 
[https://perma.cc/PD7N-TT6L]. 
 7. See Jens Boch, TALEs of Genome Targeting, NATURE BIOTECHNOLOGY 135, 
135–36 (2011); Sundar Durai et al., Zinc Finger Nucleases: Custom-Designed Molecular 
Scissors for Genome Engineering of Plant and Mammalian Cells, 33 NUCLEIC ACIDS RES. 
5978, 5978 (2005). 
 8. Even so, close to a dozen protocols involving ZFNs have been submitted to the 
Recombinant DNA Advisory Committee (“RAC”) for review to date. See, e.g., Gene 
Transfer Protocol Report: A Phase I, Open-Label, Ascending Dose Study to Assess the 
Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease 
(ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects with Severe Hemophilia 
B, GEMCRIS (Jan. 23, 2018), https://www.gemcris.od.nih.gov/Contents/GC_CLIN_
TRIAL_RPT_VIEW.asp?WIN_TYPE=R&CTID=1446 [https://perma.cc/7ER8-X557]. 
Moreover, TALEN, although nowhere near approval as a therapy, has been used to treat 
an infant outside the United States, apparently successfully. See Andrew Pollack, A Cell 
Therapy Untested in Humans Saves a Baby with Cancer, N.Y. TIMES, Nov. 6, 2015, at B3. 
 9. Kahn, supra note 1. 
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interest has resulted in thousands of scholarly publications,10 floods of 
articles in the popular press,11 and extensive debate about a broad 
range of bioethics and public policy issues, including but not limited 
to questions about safety and efficacy, about whether it is appropriate 
to edit the human germline,12 and about whether it is possible to 
establish global governance over what appears to be a potentially 
species-altering technology.13 Federal and international panels and 
commissions have addressed the science and ethics of CRISPR.14 And 
public discussion of the possibility and desirability of making 
inheritable genetic alterations to eliminate genetic disease, and of 
genetically enhancing humans, which has been simmering for nearly 
fifty years, has now reached boiling point. 
 
 10. See, e.g., Barry L. Stoddard & Keith Fox, Editorial, CRISPR in Nucleic Acids 
Research, 44 NUCLEIC ACIDS RES. 4989, 4989–90 (2016), corrected at 44 NUCLEIC ACIDS 
RES. 8512, 8512 (2016) (correcting an omission of a reference from a previous issue to 
properly explain that “the number of studies citing ‘CRISPR + Cas9,’ as indexed in 
PubMed, has exploded from four papers in 2012 to a projection of over 2000 publications 
in 2016”); Amanda B. Keener, Gene Editing: From Roots to Riches, SCIENTIST (Oct. 1, 
2016), http://www.the-scientist.com/?articles.view/articleNo/47156/title/Gene-Editing--From-
Roots-to-Riches/ [https://perma.cc/5ZZ9-NNHZ]. 
 11. See, e.g., Kendal K. Morgan, CRISPR Comes to the Clinic, GENOME MAG., 
Summer 2017, at 40, 43, 45; Alice Park, Life, the Remix, TIME, July 4, 2016, at 42, 44–48; 
Michael Specter, The Gene Hackers, NEW YORKER, Nov. 16, 2015, at 52, 54; Nathaniel 
Comfort, Can We Cure Genetic Diseases Without Slipping into Eugenics?, NATION (July 
16, 2015), http://www.thenation.com/article/can-we-cure-genetic-diseases-without-slipping-
into-eugenics/?print=1 [https://perma.cc/C9FL-2QT5]; Mike Feibus, CRISPR Gene 
Editing Tool: Are We Ready to Play God?, USA TODAY (July 24, 2017, 9:00 AM), 
https://www.usatoday.com/story/tech/columnist/2017/07/24/crispr-gene-editing-tool-we-
ready-play-god/490144001/ [https://perma.cc/5WHE-X3W7]. 
 12. See About Human Germline Gene Editing, CTR. FOR GENETICS & SOC’Y, 
http://www.geneticsandsociety.org/article.php?id=8711 [https://perma.cc/6VC6-4N6N]. 
 13. See Gary E. Marchant & Wendell Wallach, Coordinating Technology Governance, 
ISSUES SCI. & TECH., Summer 2015, at 43, 43–45. 
 14. There have been two international summits on human genome editing to date. See 
Press Release, Nat’l Acads. of Scis. Eng’g & Med., Second International Summit on 
Human Genome Editing to Be Held in Hong Kong (May 8, 2018), 
http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=05082018 
[https://perma.cc/Z9V4-K7SY]. In addition, the National Academies of Science, 
Engineering, and Medicine convened international scholarly meetings over several years 
and issued an influential report in 2017. See generally NAT’L ACADS. OF SCIS., ENG’G, & 
MED., HUMAN GENOME EDITING: SCIENCE, ETHICS, AND GOVERNANCE (2017) 
[hereinafter NASEM, HUMAN GENOME EDITING] (“Recognizing both the promise and 
concerns related to human genome editing, the National Academy of Sciences and the 
National Academy of Medicine convened the Committee on Human Gene Editing: 
Scientific, Medical, and Ethical Considerations to carry out the study that is documented 
in this report.”). And the second issue of the CRISPR Journal featured a compendium of 
position statements from around the world. See infra text accompanying note 82. 
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The prospect of genetic modification, and the fears and hopes it 
engendered, were first addressed in the 1970s in connection with the 
Asilomar moratorium on recombinant DNA research.15 Discussion of 
the ethical, legal, and social implications (“ELSI”) of genetic research 
expanded in the 1990s when recombinant DNA research in humans 
began to attempt correction of genetic defects and the Human 
Genome Project began its work of finding and mapping all human 
genes.16 Attention to the implications of gene-based treatment and 
enhancement largely faded from view, however, after the mapping 
project was completed and progress in clinical research slowed. 
Despite the growth of multidisciplinarity in the biosciences, 
collaboration between scientists and bioethics scholars has remained 
challenging because of the rapid development of specialized 
knowledge and the resultant information gaps and language barriers. 
This means that ethical and policy thinking can at times lag behind 
biotechnological developments or misunderstand or mischaracterize 
them.17 However, waiting to address the implications of a novel 
biotechnology until it is more fully developed often means chasing 
after what has rapidly become regarded as inevitable.18 Indeed, the 
global response to Dr. He’s work may exemplify both the inherent 
 
 15. At the Asilomar Conference, the American scientific community voluntarily and 
temporarily halted all recombinant DNA research until risks of harm were further 
assessed and oversight mechanisms were created. See generally Paul Berg, Asilomar 1975: 
DNA Modification Secured, 455 NATURE 290 (2008) (noting the successes of the 
conference and considering whether an Asilomar-type conference could “help resolve 
some of the controversies now confronting scientists and the public”); Michael Rogers, 
The Pandora’s Box Congress, ROLLING STONE, June 19, 1975, at 36 (narrating the historic 
conference through vignettes). 
 16. Eric D. Green, James D. Watson & Francis S. Collins, Twenty-Five Years of Big 
Biology, 526 NATURE 29, 29–31 (2015). 
 17. When five percent of the federal funding for the Human Genome Project was set 
aside for study of its ethical, legal, and social implications, bioethics scholarship went 
mainstream. See Jean E. McEwen et al., The Ethical, Legal, and Social Implications 
Program of the National Human Genome Research Institute: Reflections on an Ongoing 
Experiment, 15 ANN. REV. GENOMICS & HUM. GENETICS 481, 481–82 (2014). Yet it also 
became known for examining the potential of biotechnologies that had not yet come to 
fruition and thus was sometimes regarded as standing in the way of science. Steven Pinker, 
The Moral Imperative for Bioethics, BOS. GLOBE (Aug. 1, 2015), 
https://www.bostonglobe.com/opinion/2015/07/31/the-moral-imperative-for-bioethics/JmEkoy
zlTAu9oQV76JrK9N/story.html [https://perma.cc/5AHD-HQNM (dark archive)]. 
 18. Germline gene editing has been so characterized. See, e.g., Stephen S. Hall, Red 
Line: Will We Control Our Genetic Destinies?, SCI. AM., Sept. 2016, at 54, 56–58; Antonio 
Regalado, Engineering the Perfect Baby, MIT TECH. REV., May–June 2015, at 26, 32 
[hereinafter Regalado, Engineering the Perfect Baby]. 
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limitations of guidance development and the failures of education and 
enforcement.19 
B. Benefits, Harms, and Policy Tradeoffs 
Two overarching policy questions that scientists, scholars, and 
society began to address during the Asilomar moratorium have 
reemerged as a result of CRISPR-Cas9: First, should our concerns be 
focused only on safety and efficacy, or also on metaphysical matters 
like the integrity of human genetic inheritance?20 And second, should 
the debates and decisions be led by scientists who are experts in the 
technology; by policymakers, bioethics scholars, and the general 
public; or by the individuals and families affected by genetic 
disorders, and their advocates? 21  In the current debate about 
inheritable genetic modifications, more than a few prominent 
scientists have agreed that science alone cannot answer ethics 
questions; instead, they acknowledge the need for broad and robust 
 
 19. See discussion infra Part II; see also Antonio Regalado, Rogue Chinese CRISPR 
Scientist Cited US Report as His Green Light, MIT TECH. REV. (Nov. 27, 2018), 
https://www.technologyreview.com/s/612472/rogue-chinese-crispr-scientist-cited-us-report-
as-his-green-light/ [https://perma.cc/EG4N-VPU3]. 
 20. George J. Annas, Lori B. Andrews & Rosario Isasi, Protecting the Endangered 
Human: Toward an International Treaty Prohibiting Cloning and Inheritable Alterations, 
28 AM. J.L. & MED. 151, 151–53 (2002) [hereinafter Annas et al., Protecting the 
Endangered Human]; George Annas, Scientists Should Not Edit Genomes of Human 
Embryos, B.U. SCH. PUB. HEALTH (Apr. 30, 2015), https://www.bu.edu/sph/2015/04/30/
scientists-should-not-edit-genomes-of-human-embryos/ [https://perma.cc/U4NW-UXQM] 
[hereinafter Annas, Human Embryos]. 
 21. See, e.g., Ruha Benjamin, Interrogating Equity: A Disability Justice Approach to 
Genetic Engineering, in INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: 
COMMISSIONED PAPERS 48, 48–51 (2015), www.nationalacademies.org/cs/groups/
pgasite/documents/webpage/pga_170455.pdf [https://perma.cc/MU37-9JRV]; Alta Charo, 
The Legal/Regulatory Context, in INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: 
COMMISSIONED PAPERS, supra, at 13, 13–19; Erika Check Hayden, Tomorrow’s Children, 
530 NATURE 402, 403–05 (2016); J. Benjamin Hurlbut, Limits of Responsibility: Genome 
Editing, Asilomar, and the Politics of Deliberation, HASTINGS CTR. REP., Sept.–Oct. 2015, 
at 11, 11–14; Eric T. Juengst, Crowdsourcing the Moral Limits of Human Gene Editing?, 
HASTINGS CTR. REP., May–June 2017, at 15, 15–23; Daniel Sarewitz, Science Can’t Solve 
It, 522 NATURE 413, 413–14 (2015); Sharon F. Terry, Societal Implications: The Role of 
Advocacy Organizations, in INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: 
COMMISSIONED PAPERS, supra, at 36, 36–38; Charis Thompson, Governance, Regulation, 
and Control: Public Participation, in INTERNATIONAL SUMMIT ON HUMAN GENE 
EDITING: COMMISSIONED PAPERS, supra, at 44, 44–47; Antonio Regalado, Patients Favor 
Changing the Genes of the Next Generation with CRISPR, MIT TECH. REV. (Dec. 2, 2015), 
https://www.technologyreview.com/s/544141/patients-favor-changing-the-genes-of-the-next-
generation-with-crispr/ [https://perma.cc/M6GD-6U2X]. 
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public debate.22 But whether that ethics debate should be framed as a 
balance of the risks of harm against potential benefits only for 
individuals and their progeny, or whether it should expand to address 
the implications of multiple individual, inheritable changes for the 
human species as a whole,23 is still at issue. At the same time, the 
research is advancing rapidly and has already taken some 
unprecedented directions.24 
Scientists and the public alike recognize that potentially 
astounding health benefits could follow from editing the human 
germline. But there are real concerns as well. Introducing permanent 
inheritable changes might introduce unintended errors that could 
damage not only individual patient-subjects but also their future 
offspring for generations. This concern arose when gene-transfer 
research25 began in 1990.26 Gene transfer seeks to correct deleterious 
genetic mutations by introducing multiple copies of nonmutated 
versions of the responsible gene into the body.27 The principal risk of 
harm comes from the possibility of “off-target effects”—that is, that 
copies could insert into the wrong place in the genome, causing a 
different and potentially deleterious mutation.28 That potential harm 
is only to the individual so treated; however, it is common to monitor 
 
 22. See, e.g., Eric S. Lander, Brave New Genome, 373 NEW ENG. J. MED. 5, 5–8 
(2015). 
 23. See Annas et al., Protecting the Endangered Human, supra note 20, at 153; Annas, 
Human Embryos, supra note 20. 
 24. Chinese researchers in particular have surged ahead in both embryo research and 
clinical applications, and He Jiankui was not the first to surprise the scientific community. 
See discussion infra Part II. 
 25. Gene-transfer research was first misleadingly labeled “gene therapy.” See Nancy 
M.	P. King, Rewriting the “Points to Consider”: The Ethical Impact of Guidance Document 
Language, 10 HUM. GENE THERAPY 133, 133 (1999). It has now been renamed “gene 
augmentation” or “gene-addition” research to distinguish it from gene editing. See Thierry 
VandenDriessche & Marinee K. Chuah, CRISPR-Cas9 Flexes Its Muscles: In Vivo Somatic 
Gene Editing for Muscular Dystrophy, 24 MOLECULAR THERAPY 414, 414–16 (2016). 
 26. Coutts, supra note 5, at 63. The first human clinical gene-transfer experiment that 
intended to develop a genetic treatment enrolled children with adenosine deaminase 
deficiency, a severe combined immunodeficiency disorder. Francesca Ferrua & 
Alessandro Aiuti, Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble 
Babies to an Approved Drug, 28 HUM. GENE THERAPY 972, 972–74 (2017). The first 
patient-subject in that experiment, Ashanti DeSilva, is still alive and well. See id. at 978. 
 27. See LEROY WALTERS & JULIE GAGE PALMER, THE ETHICS OF HUMAN GENE 
THERAPY 18, 23, 26, 166–69 (1997); Nancy M. P. King, Accident & Desire: Inadvertent 
Germline Effects in Clinical Research, HASTINGS CTR. REP., Mar.–Apr. 2003, at 23, 24 
[hereinafter King, Accident & Desire]; VandenDriessch & Chuah, supra note 25.  
 28. The principal concern is that an off-target insertion will cause cancer. See, e.g., 
Salima Hacein-Bey-Abina et al., Efficacy of Gene Therapy for X-Linked Severe Combined 
Immunodeficiency, 363 NEW ENG. J. MED. 355, 363 (2010). 
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adult male patient-subjects in many gene-transfer clinical trials by 
testing their semen to determine whether there are any potential 
germline effects and to advise them against unprotected sex until 
monitoring is completed.29 
Gene editing, in contrast, does not flood the organism with new 
copies of genes.30 Instead, it either removes mutated or damaged 
sequences from genes, or removes them and replaces them with 
undamaged versions.31 One of the reasons that gene editing has 
generated such scientific excitement is that it seems to be significantly 
more precise, and potentially more accurate, as well as more effective 
and more reliably permanent, than gene addition at its best.32 
The key to gene editing is the creation of double-strand breaks in 
the DNA double helix. Gene editing before CRISPR used ZFNs and 
TALENs; these methods, which are still in use, required very precise 
and painstaking construction of the proteins that break DNA, called 
nucleases, to hit the right places where the DNA should be broken 
(called cleavage sites).33 The discovery of CRISPR has rapidly led to 
technologies that are much simpler and easier to use.34 
 
 29. The risk of germline effects from somatic cell gene-transfer interventions 
historically arose only by accident. See, e.g., Katherine A. High, Gene Therapy for 
Hemophilia: The Clot Thickens, 25 HUM. GENE THERAPY 915, 918 (2014). The semen of 
some male gene-transfer research subjects was found to contain copies of the viral vector 
used to insert the transgene into their somatic cells. Id. at 918 fig.3 (collecting well-
publicized incidents of such occurrence). This discovery led to monitoring of male patient-
subjects; in gene-transfer trials using systemic administration of the vector-transgene 
combination, semen is collected and tested to look for copies of the (deactivated) viral 
vector used to carry the transgene into the body’s cells. Id. at 918. Persistence of vector has 
always been temporary and has never appeared to include transgene or to affect sperm. Id. 
This low risk of germline effects nonetheless raised concerns and has influenced study 
design, altering the choice of vector in some gene-transfer protocols and the route of 
administration of the vector-transgene combination in others, in order to reduce the 
likelihood of germline transmission. See id. at 917–19; King, supra, at 23–26. In this 
author’s opinion, concern about germline effects may have contributed to Jesse 
Gelsinger’s death in a phase one gene-transfer protocol, because the FDA changed the 
route of administration of the gene-transfer intervention from injection into the peripheral 
circulation to injection into a vein leading directly to the liver, reasoning that the former 
route was systemic and thus more likely to risk germline effects. Targeting the liver proved 
more dangerous, however, as it provoked an overwhelming immune response that led to 
Gelsinger’s death. 
 30. See Rodolphe Barrangou & Jennifer A. Doudna, Applications of CRISPR 
Technologies in Research and Beyond, 34 NATURE BIOTECHNOLOGY 933, 933–36 (2016). 
 31. See id. at 934 (offering a short primer on CRISPR). 
 32. See generally id. (overviewing the wide variety of advantages CRISPR brings, 
both generally and as applied to specific industries and research fields). 
 33. See id. at 933. For excellent discussions of all three biotechnologies, see generally 
Thomas Gaj, Charles A. Gersbach & Carlos F. Barbas III, ZFN, TALEN, and 
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CRISPR-Cas9 is the first and most popular of the new gene-
editing tools to be discovered and developed to date.35 It is stable, 
simple, facile, affordable, specific, and highly versatile, able to target 
any DNA sequence, to remove mutated sequences, and even to 
replace them with nonmutated sequences.36 In comparison with the 
imprecision of gene addition or augmentation, gene-editing 
techniques appear to more precisely control the integration of new 
genetic information, thereby decreasing (though not completely 
eliminating) the possibility of harmful insertional mutagenesis and 
other off-target effects.37 And CRISPR-Cas9 is so easy to use that kits 
can be purchased online, enabling many scientists and students to 
 
CRISPR/Cas9-Based Methods for Genome Engineering, 31 TRENDS BIOTECHNOLOGY 
397 (2013); Rajat M. Gupta & Kiran Musunuru, Expanding the Genetic Editing Tool Kit: 
ZFNs, TALENs, and CRISPR-Cas9, 124 J. CLINICAL INVESTIGATION 4154 (2014); and 
Keener, supra note 10.  
 34. In 1993, Francisco Mojica identified multiple copies of palindromic repetitive 
bases, interspaced with unique DNA spacers, in the DNA of a microbe. Eric S. Lander, 
The Heroes of CRISPR, 164 CELL 18, 18 (2016). Its structural similarity to another 
clustered repeat sequence with spacers that had previously been identified in a common 
bacterium suggested biological significance across species. Yoshizumi Ishino et al., 
Nucleotide Sequence of the IAP Gene, Responsible for Alkaline Phosphatase Isozyme 
Conversion in Escherichia Coli, and Identification of the Gene Product, 169 J. 
BACTERIOLOGY 5429, 5432 (1987). These repetitive genetic sequences came to be known 
as CRISPR. Mojica’s work outlining CRISPR’s likely function as an adaptive defense 
mechanism, able to cut foreign DNA in order to cripple the ability of an invading virus to 
replicate and damage the host, was published in early 2005. See Francisco J.M. Mojica et 
al., Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign 
Genetic Elements, 60 J. MOLECULAR EVOLUTION 174, 180–81 (2005). Over the next 
decade, CRISPR’s mechanism of action was examined and elucidated further. See Samuel 
H. Sternberg & Jennifer A. Doudna, Expanding the Biologist’s Toolkit with CRISPR-
Cas9, 58 MOLECULAR CELL 568, 568 (2015). It has now been developed into a highly 
specific gene-editing tool. 
 35. See Le Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, 
339 SCIENCE 819, 819–20, 822 (2013); Giedrius Gasiunas et al., Cas9-crRNA 
Ribonucleoprotein Complex Mediates Specific DNA Cleavage for Adaptive Immunity in 
Bacteria, 109 PROC. NAT’L ACAD. SCI. 2579, 2579, 2585 (2012); Martin Jinek et al., A 
Programmable Dual-RNA-Guided Endonuclease in Adaptive Bacterial Immunity, 337 
SCIENCE 816, 816, 820 (2012); Morgan L. Maeder & Charles A. Gersbach, Genome-
Editing Technologies for Gene and Cell Therapy, 24 MOLECULAR BIOLOGY 430, 434–35 
(2016). 
 36. See Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of 
Genome Engineering with CRISPR-Cas9, 346 SCIENCE 1077 passim (2014); Young-Il Jo et 
al., CRISPR-Cas9 System as an Innovative Genetic Engineering Tool: Enhancements in 
Sequence Specificity and Delivery Methods, 1856 BIOCHIMICA ET BIOPHYSICA ACTA 234, 
234–36 (2015); Yue Mei et al., Recent Progress in CRISPR-Cas9 Technology, 43 J. 
GENETICS & GENOMICS 63, 63–64, 71, 73 (2016). 
 37. Maeder & Gersbach, supra note 35, at 433–34. 
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explore gene editing in almost any laboratory setting, or even at 
home.38 
Newer CRISPR models and related technologies are rapidly 
being developed and tested. Such refinements are continually 
underway to make gene-editing systems simpler, smaller, and more 
precise.39 In particular, editing RNA (using Cas13 instead of Cas9) 
has some advantages over editing DNA.40 Unlike DNA editing, RNA 
editing is temporary.41 An RNA edit is therefore reversible if it goes 
wrong in any way, and it can be applied to correct transient 
conditions, such as damage caused by inflammation resulting from an 
infection.42 RNA edits are also effective when cells are not actively 
dividing, whereas DNA edits are linked to cell division. 43  This 
difference means that RNA editing, unlike DNA editing, can be 
applied to brain and muscle cells, as well as to cell types found in 
other tissues.44 Finally, RNA edits affect individual bases in the 
sequences of base pairs that make up genes—and because single-base 
mutations cause a number of human genetic diseases, RNA editing 
could have the potential to treat those diseases precisely and 
effectively (though not permanently).45 
Another widely heralded improvement is base editing. Instead of 
engineering double-strand breaks of DNA, that is, removing an entire 
 
 38. Park, supra note 11, at 45; see also infra text accompanying note 128. For more 
information on biohacking in general, see Joe Brophy, God’s Name in Vein: Biohacker 
Injects Himself with DNA Sequence Made from Bible and Koran Verses, THE SUN (Dec. 
21, 2018, 12:58 AM), https://www.thesun.co.uk/news/8014880/biohacker-injects-dna-
sequence-bible-koran-verses/ [https://perma.cc/LD67-XQ3W]. 
 39. See, e.g., Janice S. Chen et al., Enhanced Proofreading Governs CRISPR-Cas9 
Targeting Accuracy, 550 NATURE 407, 407–10 (2017). 
 40. See, e.g., Jon Cohen, ‘Base Editors’ Open New Way to Fix Mutation: Novel 
CRISPR-Derived Technologies Surgically Alter a Single DNA or RNA Base, 358 SCIENCE 
432, 432–33 (2017); David B.T. Cox et al., RNA Editing with CRISPR-Cas13, 358 SCIENCE 
1019, 1019–27 (2017). 
 41. Julia Belluz & Umair Irfan, 2 New CRISPR Tools Overcome the Scariest Parts of 
Gene Editing, VOX (Oct. 25, 2017, 1:00 PM), https://www.vox.com/2017/10/25/
16527370/crispr-gene-editing-harvard-mit-broad [http://perma.cc/M3YD-U5ZH]. 
 42. Id. 
 43. Id. 
 44. Id. 
 45. Id. But see Jon Cohen, Powerful CRISPR Cousin Accidentally Mutates RNA 
While Editing DNA Target, SCIENCE (Apr. 17, 2019, 4:10 PM), 
https://www.sciencemag.org/news/2019/04/powerful-crispr-cousin-accidentally-mutates-rna-
while-editing-dna-target [https://perma.cc/56QW-CCRR] (“[T]he weaknesses of base 
editors have become increasingly apparent, and a new study shows they can also 
accidentally mutate the strands of RNA that help build proteins or perform other key 
cellular tasks.”). 
97 N.C. L. REV. 1051 (2019) 
2019] GENE-EDITING RESEARCH 1063 
 
step in the ladder of the double helix and then either allowing the 
ends to reconnect without the missing step or inserting a repaired 
replacement, base editing targets individual base pairs without 
breaking the strand.46 Paired combinations of just four proteins make 
up all human DNA, and thousands of human diseases are known to 
be caused by mutations in just one base pair of matched proteins in 
one gene. 47  For example, a mistake that puts one adenosine-
thymidine (“A-T”) pair where a guanine-cytosine (“G-C”) pair 
should be causes half of known human genetic diseases.48 Therefore, 
using base editing to change A-T pairs to G-C pairs could 
permanently and precisely correct a great many deleterious 
mutations.49 Base editing with an enzyme specially synthesized for this 
purpose is being studied in cell cultures and in small animal models,50 
and has been pronounced successful in human embryos with Marfan 
syndrome in a paper by Chinese researchers.51 
Is it possible for ethics and policy to keep up with the breakneck 
pace of this science? Maybe; but it sure ain’t easy. 
II.  A BRIEF HISTORY OF CRISPR NEWS AND POLICY 
Gene editing made headlines in March 2015 when a group of 
senior scientists and scholars led by Jennifer Doudna published 
recommendations arising from a California conference that invited 
comparison with the 1970s Asilomar moratorium on recombinant 
DNA research.52 They recommended a moratorium on “germline 
genome modification for clinical application in humans, while 
societal, environmental, and ethical implications of such activity are 
 
 46. Belluz & Irfan, supra note 41; see also Nicole M. Gaudelli et al., Programmable 
Base Editing of A-T to G-C in Genomic DNA Without DNA Cleavage, 551 NATURE 464, 
464–65 (2017); Alexis C. Komor et al., Programmable Editing of a Target Base in Genomic 
DNA Without Double-Stranded DNA Cleavage, 533 NATURE 420, 420–24 (2016); Brian S. 
Plosky, CRISPR-Mediated Base Editing Without DNA Double-Strand Breaks, 62 
MOLECULAR CELL 477, 477–78 (2016). 
 47. Belluz & Irfan, supra note 41. 
 48. Gaudelli et al., supra note 46, at 464. 
 49. Id. 
 50. See, e.g., Yuanwu Ma et al., Letter to the Editor, Highly Efficient and Precise Base 
Editing by Engineered dCas9-Guide tRNA Adenosine Deaminase in Rats, 4 CELL 
DISCOVERY 1, 1–3 (2018). 
 51. Yantinq Zeng et al., Correction of the Marfan Syndrome Pathogenic FBN1 
Mutation by Base Editing in Human Cells and Heterozygous Embryos, 26 MOLECULAR 
THERAPY 2631, 2631–32 (2018). 
 52. David Baltimore, A Prudent Path Forward for Genomic Engineering and 
Germline Gene Modification, 348 SCIENCE 36, 36–38 (2015). 
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discussed among scientific and governmental organizations.”53 They 
called for discussion of information and education about the science 
and its implications, asked that a “globally representative group” be 
convened to make policy recommendations, and sought support for 
“transparent research to evaluate .	.	. genome engineering 
technology” to examine “its potential applications for germline gene 
therapy.”54 At around the same time, the International Society for 
Stem Cell Research (“ISSCR”) issued a similar position statement.55 
And a week later, another group of scientists published a sterner call 
for a moratorium accompanied by international dialogue “to assess 
whether, and under what circumstances—if any—future research 
involving genetic modification of human germ cells should take 
place.”56 
Almost immediately thereafter, Protein & Cell published the 
results of a Chinese experiment attempting CRISPR-Cas9 
modification of nonviable human embryos with the apparent aim of 
determining the feasibility of moving to therapeutic genome editing in 
viable human embryos.57 The Chinese researchers’ findings of both 
off-target insertions and mosaicism—that is, successful editing of 
some but not all of the embryos’ cells, resulting in a “mosaic” pattern 
of edited and unedited cells—were troubling; so was their failure to 
conduct more basic research first.58 
At the end of April 2015, the National Institutes of Health 
(“NIH”) announced that it would not fund any use of gene-editing 
technology in human embryos.59 And in the summer and fall of 2015, 
several additional position statements appeared.60 A joint statement 
by the American Society of Gene and Cell Therapy (“ASGCT”) and 
 
 53. Id. at 37. 
 54. Id. 
 55. Statement, Int’l Soc’y for Stem Cell Research, The ISSCR Statement on Human 
Germline Genome Modification (Mar. 19, 2015), http://www.isscr.org/docs/default-
source/guidelines/isscr-statement-on-human-germline-genome-modification.pdf?sfvrsn=2 
[https://perma.cc/TPC9-5XV6]. 
 56. Edward Lanphier et al., Don’t Edit the Human Germ Line, 519 NATURE 410, 411 
(2015). 
 57. Puping Liang et al., CRISPR/Cas9-Mediated Gene Editing in Human 
Tripronuclear Zygotes, 6 PROTEIN & CELL 363, 363 (2015). 
 58. Id. at 366. 
 59. Statement, Nat’l Insts. of Health, Statement on NIH Funding of Research Using 
Gene-Editing Technologies in Human Embryos (Apr. 29, 2015) (on file with the North 
Carolina Law Review). 
 60. See infra text accompanying notes 61–63. 
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the Japan Society of Gene Therapy (“JSGT”)61 joined the more 
cautious side of the discussion. Echoing the initial statement from 
Doudna’s group, statements by the Hinxton Group 62  and the 
International Bioethics Committee of the United Nations63 raised 
cautions but did not call for a halt on gene-editing research that could 
affect the human germline. 
The Doudna group’s call for global attention came to fruition in 
early December 2015, with the First International Summit on Human 
Genome Editing.64 On December 3, the summit issued a statement 
that closely tracked the Doudna group’s recommendations: basic and 
preclinical research should go forward, somatic cell gene editing 
should go forward in clinical application, germline gene editing 
should not head toward the clinic, and an ongoing international forum 
should be created to continue discussion of the ELSI of gene 
editing.65 
That forum, the Committee on Human Gene Editing of the 
National Academies, was created immediately after the summit. The 
committee held international meetings examining the state of the 
science, the potential for clinical benefit, the risks of harm, and the 
ELSI of human gene-editing technologies.66 It also considered and 
assessed existing standards, oversight mechanisms, and safeguards 
 
 61. Theodore Friedmann et al., ASGCT and JSGT Joint Position Statement on 
Human Genomic Editing, 23 MOLECULAR THERAPY 1282, 1282 (2015). 
 62. Statement, Hinxton Grp., Statement on Genome Editing Technologies and 
Human Germline Genetic Modification (Sept. 10, 2015) (on file with the North Carolina 
Law Review). 
 63. See generally Int’l Bioethics Comm., UNESCO, Rep. of the Int’l Bioethics Comm. 
on Updating its Reflection on the Human Genome and Human Rights, U.N. Doc. 
SHS/YES/IBC-22/15/2 REV.2 (Oct. 2, 2015) (discussing various ethical challenges posed 
by gene editing of the human genome without calling for an outright ban on the practice in 
the future). 
 64. See STEVEN OLSON, NAT’L ACADS. OF SCIS., ENG’G, & MED., INTERNATIONAL 
SUMMIT ON HUMAN GENE EDITING: A GLOBAL DISCUSSION 6–7 (2015). For a sampling 
of the broad range of views included in the summit, see generally INTERNATIONAL 
SUMMIT ON HUMAN GENE EDITING: COMMISSIONED PAPERS, supra note 21. 
 65. Statement, Nat’l Acads. of Scis. Eng’g & Med., On Human Gene Editing: 
International Summit Statement (Dec. 3, 2015), http://www.nap.edu/21913 
[https://perma.cc/PFE6-Y9X2]; see also Sara Reardon, Global Summit Reveals Divergent 
Views on Human Gene Editing, 528 NATURE 173, 173 (2015). See generally 
INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: COMMISSIONED PAPERS, supra 
note 21 (presenting various issues on which the summit took a position). 
 66. Consensus Study, NAT’L ACADEMIES SCI., ENGINEERING & MED., 
http://www.nationalacademies.org/gene-editing/consensus-study/index.htm [http://perma.cc/
5HFT-AEYC]. 
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worldwide.67 Its final report, Human Genome Editing: Science, Ethics, 
and Governance, appeared in February 2017.68 The report’s widely 
anticipated recommendations have generally been interpreted as 
opening the doors to the future a little wider, in two respects. First, 
the report recommends limiting human clinical trials of somatic gene 
editing to prevention and treatment applications “at this time” and 
calls for public discussion and policy debate on enhancement 
applications, thus setting the stage for enhancement research in the 
future.69 Second, it recommends permitting human germline gene 
editing, but only for compelling purposes—that is, when there are no 
reasonable alternatives and the intervention is intended to prevent or 
treat serious disease or disability.70 The report thus even more clearly 
sets the stage for germline interventions in the not-too-distant future, 
depending on what counts as a reasonable alternative. 71  It also 
requires rigorous and comprehensive oversight and long-term 
multigenerational follow-up and recommends transnational 
cooperation and ongoing public reassessment.72 
The summer of 2017 saw a number of additional developments. 
The American College of Medical Genetics and Genomics published 
a points-to-consider document on genome editing in clinical 
genetics;73 it concluded that “genome editing in the human embryo is 
premature” and strongly encouraged “broad public debate,” 
continued research to resolve technological problems, and resisting 
pressure for premature clinical application.74 Shortly thereafter, the 
American Society of Human Genetics led a large group of genetics 
and medical organizations that published a comprehensive joint 
position statement on human-germline genome editing, which divided 
the ethical issues into those arising from its failure and those arising 
from its success,75 and concluded that “at this time,” germline gene 
editing intended for human pregnancy is “inappropriate,” but in vitro 
 
 67. Id. 
 68. NASEM, HUMAN GENOME EDITING, supra note 14. 
 69. Id. at 133–39. 
 70. Id. at 134. 
 71. Id. at 134–35. 
 72. Id. 
 73. ACMG Bd. of Dirs., Am. Coll. of Med. Genetics & Genomics, Genome Editing in 
Clinical Genetics: Points to Consider—A Statement of the American College of Medical 
Genetics and Genomics, 19 GENETICS MED. 723, 723–24 (2017). 
 74. Id. at 724. 
 75. Kelly E. Ormond et al., Human Germline Genome Editing, 101 AM. J. HUM. 
GENETICS 167, 167–76 (2017). 
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human germline-editing research should go forward and should be 
publicly funded.76  Echoing the Human Gene Editing report, the 
position statement further argued that human clinical applications of 
germline editing should not proceed unless there is a compelling 
medical and ethical rationale, good preclinical evidence, and a 
transparent public process.77 
Finally, the first human-embryo editing in the United States 
came to light in the summer of 2017. Oregon Health Sciences 
University’s (“OHSU”) Shoukrat Mitalipov and his team edited 
viable human zygotes, which they created using healthy oocytes and 
sperm containing a genetic mutation that causes hypertrophic 
cardiomyopathy, and which thus had a 50/50 chance of carrying the 
mutation.78 They edited these zygotes with a CRISPR-Cas9 package 
that included a normal synthetic copy of the mutated gene so that the 
mutation could be replaced with the synthetic copy.79 Their published 
results claimed a high degree of success with few off-target effects and 
almost no mosaicism, but did contain a surprising wrinkle: the normal 
gene was not the synthetic version but a copy of the normal version 
found in the oocyte genome.80 These results have been questioned as 
improbable.81 It seems likely that a definitive answer will emerge only 
 
 76. Id. at 172–73. 
 77. Id. at 173–74. 
 78. Hong Ma et al., Correction of a Pathogenic Gene Mutation in Human Embryos, 
548 NATURE 413, 413–16 (2017). 
 79. Id. 
 80. Id. at 416–18. Not surprisingly, there was considerable discussion triggered by this 
revelation in the science-oriented popular press about the ethics of gene editing human 
embryos, with some particularly skeptical. See, e.g., Eliza Barclay, Scientists Successfully 
Used CRISPR to Fix a Mutation that Causes Disease. This Is Huge., VOX (Aug. 2, 2017, 
3:50 PM), https://www.vox.com/science-and-health/2017/8/2/16083300/crispr-heart-disease 
[http://perma.cc/R24J-EHT9]; Sharon Begley, U.S. Scientists Edit Genome of Human 
Embryo, but Cast Doubt on Possibility of ‘Designer Babies,’ STAT (Aug. 2, 2017), 
www.statnews.com/2017/08/02/crispr-designer-babies/?utm [http://perma.cc/L8M3-ZKSP]; 
Jessica Berg, Editing Human Embryos with CRISPR Is Moving Ahead—Now’s the Time 
to Work Out the Ethics, CONVERSATION (July 28, 2017, 11:40 AM), 
https://theconversation.com/editing-human-embryos-with-crispr-is-moving-ahead-nows-the-
time-to-work-out-the-ethics-81732 [http://perma.cc/PC4W-99G3]; Emily Mullin, Gene 
Editing Study in Human Embryos Points Toward Clinical Trials, MIT TECH. REV. (Aug. 
2, 2017), https://www.technologyreview.com/s/608482/gene-editing-study-in-human-embryos-
points-toward-clinical-trials/ [http://perma.cc/R24J-EHT9]; Kelly Servick, First US-Based 
Group to Edit Human Embryos Brings Practice Closer to Clinic, SCIENCE (Aug. 2, 2017, 
1:00 PM), https://www.sciencemag.org/news/2017/08/first-us-based-group-edit-human-embryos-
brings-practice-closer-clinic [http://perma.cc/7PEP-3CQ5]. 
 81. Skeptical researchers argue that the editing process may simply have deleted a 
portion of DNA that included the mutation, and that Mitalipov’s team detected the one 
remaining normal maternal gene, not two copies of it, but the team has responded that 
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if there is continued research by other teams attempting to duplicate 
OHSU’s results. 
All things considered, it should be clear by now that human 
genome editing is of enormous social and policy interest, but keeping 
track of the position papers, reports, guidances, and commentaries is 
as much of a challenge as keeping up with the science. There is even a 
journal devoted entirely to CRISPR, and its second issue contains a 
useful compilation and review of the many statements relating to the 
ethical and policy implications of the science—but that list appeared 
in print in early 201882 and already needs updating. Most notably, the 
Second International Summit on Human Genome Editing took place 
in Hong Kong on November 27–29, 2018.83 It included a hastily 
rearranged session featuring He Jiankui, whose claim of having 
brought gene-edited twins to live birth had shocked the world just 
days before.84 The repercussions of Dr. He’s work are still being felt, 
and new and amended policy and guidance documents are being 
published and prepared.85 
In brief, Dr. He, a Chinese national who studied in the United 
States while developing his embryo-editing plans, claims to have 
edited the genomes of twin girls at fertilization in order to increase 
their resistance to HIV infection.86 Dr. He has also claimed that 
another pregnancy resulting from his research was underway as of 
 
two copies of the maternal gene have been detected and that as-yet-unpublished work 
confirms that gene repair preferentially seeks the healthy maternal gene. Ewen Callaway, 
Did CRISPR Really Fix a Genetic Mutation in These Human Embryos?, NATURE (Aug. 8, 
2018), https://www.nature.com/articles/d41586-018-05915-2 [http://perma.cc/Q9BU-4KPX]. 
 82. Carolyn Brokowski, Do CRISPR Germline Ethics Statements Cut It?, 1 CRISPR J. 
115, 115–23 (2018). 
 83. The summit website includes agenda information, slide presentations, videos, and 
a concluding statement. Second International Summit on Human Genome Editing, NAT’L 
ACADEMIES SCI., ENGINEERING & MED., http://www.nationalacademies.org/gene-
editing/2nd_summit/ [http://perma.cc/RYX5-GJAS]. 
 84. Regalado, Chinese Scientists, supra note 3. 
 85. For example, eight European specialty societies have published a statement in 
response to Dr. He’s work. Hildegard Büning et al., Consensus Statement of European 
Societies of Gene and Cell Therapy on the Reported Birth of Genome-Edited Babies in 
China, 29 HUM. GENE THERAPY 1337, 1337–38 (2018). Other work is still underway. See, 
e.g., Sharon Begley, After ‘CRISPR Babies,’ International Medical Leaders Aim to Tighten 
Gnome Editing Guidelines, STAT (Jan. 24, 2019), https://www.statnews.com/2019/01/
24/crispr-babies-show-need-for-more-specific-rules/?utm_content=buffer3335a&utm_medium=
social&utm_source=twitter&utm_campaign=twitter_organic [https://perma.cc/BMV7-HFVT]. 
 86. Marilynn Marchione, Chinese Researcher Claims First Gene-Edited Babies, 
ASSOCIATED PRESS (Nov. 26, 2018), https://www.apnews.com/4997bb7aa36c45449b488e19
ac83e86d [http://perma.cc/6NXR-GE76]. 
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late November 2018.87 These claims were recently substantiated by 
Chinese authorities,88 but there is still no peer-reviewed publication of 
Dr. He’s research at the time of this writing, and scientists who 
reviewed the slides he presented at the summit in Hong Kong are 
skeptical about his data.89 Dr. He presented his claims to the world in 
a YouTube video,90 and reporter Antonio Regalado broke the story 
of his work in the MIT Technology Review shortly before the summit 
began.91 
Apparently, Dr. He recruited couples in which the man has HIV 
infection and the woman does not and told them that he was 
conducting HIV vaccine research.92 Dr. He collected sperm and ova 
from the man and woman, washed the sperm before fertilizing the 
ovum with it—which is well known to render transmission of HIV to 
the embryo virtually impossible—and then sought to edit out a gene 
that plays a role in helping HIV enter cells, ostensibly to increase the 
resulting child’s resistance to HIV infection. 93  Crucially, Dr. He 
admitted that the edit was not successful in one of the embryos, and it 
is unclear whether it was completely or even partially successful in the 
other.94 In addition, it is probable that disabling or deleting the gene 
in question decreases resistance to other, more common infections.95 
 
 87. Ashley P. Taylor, Second CRISPR-Modified Pregnancy May Be Underway, 
SCIENTIST (Nov. 28, 2018), https://www.the-scientist.com/news-opinion/second-crispr-
modified-pregnancy-may-be-underway-65151 [http://perma.cc/V8BG-MQPV]. 
 88. Phoebe Zhang, China Confirms Birth of Gene-Edited Babies, Blames Scientist He 
Jiankui for Breaking Rules, S. CHINA MORNING POST (Feb. 4, 2019, 11:47 AM), 
https://www.scmp.com/news/china/science/article/2182964/china-confirms-gene-edited-babies-
blames-scientist-he-jiankui [https://perma.cc/TDE7-DA9K]. 
 89. See Katarina Zimmer, CRISPR Scientists Slam Methods Used on Gene-Edited 
Babies, SCIENTIST (Dec. 4, 2018), https://www.the-scientist.com/news-opinion/crispr-
scientists-slam-methods-used-on-gene-edited-babies--65167 [http://perma.cc/Z3VY-MVQK]; 
see also Amy Dockser Marcus, Scientists Skeptical About Gene-Edited Baby Experiment, 
WALL ST. J. (Dec. 12, 2018, 7:00 AM), https://www.wsj.com/articles/gene-edited-babies-
experiment-raises-concerns-11544616000 [http://perma.cc/K6FR-WMBT]. See generally 
Sean P. Ryder, #CRISPRbabies: Notes on a Scandal, 1 CRISPR J. 355, 355–57 (2018) 
(noting that there are enough uncertainties about Dr. He’s work to “raise clear scientific 
objections”); Ed Yong, The CRISPR Baby Scandal Gets Worse by the Day, ATLANTIC 
(Dec. 3, 2018), https://www.theatlantic.com/science/archive/2018/12/15-worrying-things-
about-crispr-babies-scandal/577234/ [http://perma.cc/F3XT-WH9P] (detailing fifteen 
“worrying things” about Dr. He’s research). 
 90. The He Lab, supra note 3. 
 91. See Regalado, Chinese Scientists, supra note 3. 
 92. See Marchione, supra note 86. 
 93. Regalado, Chinese Scientists, supra note 3; see also Marchione, supra note 86. 
 94. See Marchione, supra note 86; Zimmer, supra note 89; see also Ryder, supra note 
89, at 355. 
 95. See Marchione, supra note 86; Zimmer, supra note 89. 
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Moreover, the embryos were not infected or diseased in any way; 
such an edit constitutes prevention, or enhancement, rather than 
treatment (and of course, there are many other, far less invasive ways 
to prevent HIV infection).96 Thus, bringing these edited embryos to 
live birth violates every guidance document and every ethical and 
policy standard in place around the world. Questions also abound 
about the validity of regulatory approvals Dr. He claims to have 
obtained and the clarity, completeness, and accuracy of the consent 
form signed by the couple.97 The Chinese government has condemned 
Dr. He’s work and suspended all his activities.98 
And yet, Dr. He has managed to claim the spotlight and rekindle 
fierce debate about clinical applications of CRISPR.99 Scientific and 
policy developments therefore seem to be leading inexorably—and 
pretty swiftly—toward an expansive research portfolio and clinical 
applications of gene editing. So now it is time to ask: Why not? 
III.  WHAT ARE THE ETHICAL AND POLICY ISSUES IN GENE 
EDITING? 
Editing the human germline might be an accidental attribute of a 
genuinely successful gene-editing treatment, or it might be gene 
editing’s true goal. Does the difference matter? Well, yes, if it points 
toward enhancement applications and thereby complicates 
consequent policy implications. Questions of oversight and 
governance, access and cost, and even more basically, whether and if 
so how tightly future clinical applications of the technology should be 
controlled, all need to address how far it is okay to go. 
 
 96. Yong, supra note 89; see also Catherine Offord, Claim of First Gene-Edited Babies 
Triggers Investigation, SCIENTIST (Nov. 26, 2018), https://www.the-scientist.com/news-
opinion/claim-of-first-gene-edited-babies-triggers-investigation-65139 [http://perma.cc/5RTP-
K6F4]. 
 97. See Yong, supra note 89; see also Xiaomei Zhai et al., Chinese Bioethicists 
Respond to the Case of He Jiankui, HASTINGS CTR. (Feb. 7, 2019), 
https://www.thehastingscenter.org/chinese-bioethicists-respond-case-jiankui/ [https://perma.cc/
8VT3-3428]. 
 98. Offord, supra note 96; Antonio Regalado, The Chinese Scientist Who Claims He 
Made CRISPR Babies Is Under Investigation, MIT TECH. REV. (Nov. 26, 2018), 
https://www.technologyreview.com/s/612466/the-chinese-scientist-who-claims-he-made-crispr-
babies-has-been-suspended-without-pay/ [http://perma.cc/X6CE-C2F3]. 
 99. See supra notes 84–85 and accompanying text. 
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A. Is Germline Genome Editing Necessary, or Just Way Cool? 
Avoiding disease by means of genetic intervention requires 
knowing which genes are involved in disease causation. Once genes 
have been identified, treatments are generally sought for affected 
individuals and designed to be applied to somatic cells—that is, to 
edit the DNA in the affected cells of the individual’s body. Somatic 
cell genetic correction has been the goal of human genetic 
manipulation since its beginning.100 Correction of the genetic defects 
in all or most of the affected somatic cells of an individual with a 
known genetic disorder would, by definition, be a treatment—even a 
cure—for that person.101 Gene-editing research designed to correct 
genetic defects in the somatic cells of adults or children is less likely to 
pose a risk of inadvertent germline effects than is gene-addition 
research.102 Thus, it is far less problematic, as long as standards of 
safety and efficacy are met.103 
A representative gene-editing example is Sangamo Therapeutics’ 
trial of an in vivo gene-editing intervention for Hunter syndrome, or 
mucopolysaccharidosis type II, using ZFNs. 104  The first patient-
 
 100. See generally WALTERS & PALMER, supra note 27, at 17–59 (describing the 
science and ethics of somatic cell gene therapy, which affects the research subject or 
patient but not future generations, and which still represents the only type of genetic 
research intervention or genetic treatment permissible in humans). 
 101. See id. 
 102. Sharon Begley, They’re Going to CRISPR People. What Could Possibly Go 
Wrong?, STAT (June 23, 2016), https://www.statnews.com/2016/06/23/crispr-humans-
penn-clinical-trial/ [http://perma.cc/DUD7-XBBT]. 
 103. See, e.g., Kaiwen Ivy Liu et al., A Chemical-Inducible CRISPR-Cas9 System for 
Rapid Control of Gene Editing, 12 NATURE CHEMICAL BIOLOGY 980, 980–82 (2016); see 
also Begley, supra note 102. Nonetheless, it matters whether the gene-editing tool used 
simply snips out the defective sequence and allows the DNA to rejoin without it—a 
process known as nonhomologous end joining—or whether the defective sequence is 
replaced with a nonmutated sequence, which is known as homologous recombination or 
homology directed repair. Nonhomologous end joining is now known to be less precise 
than homology-directed repair; it also raises the interesting possibility that merely deleting 
the mutated sequence could also delete potentially beneficial genetic information and thus 
be as harmful as it is helpful. See, e.g., Moises Velasquez-Manoff, Opinion, The Upside of 
Bad Genes, N.Y. TIMES (June 17, 2017), https://www.nytimes.com/2017/06/17/
opinion/sunday/crispr-upside-of-bad-genes.html [http://perma.cc/67WS-EVUW]. 
 104. Jocelyn Kaiser, A Human Has Been Injected with Gene-Editing Tools to Cure His 
Disabling Disease. Here’s What You Need to Know, SCIENCE (Nov. 15, 2017), 
http://www.sciencemag.org/news/2017/11/human-has-been-injected-gene-editing-tools-cure-his-
disabling-disease-here-s-what-you [http://perma.cc/PE4J-PLYX]. More recently, University of 
Pennsylvania researchers began a trial using CRISPR-Cas9 to alter the T cells of adult 
patient-subjects with cancer. See Shawna Williams, Two Patients Treated with CRISPRed 
Cells in Immunotherapy Trial, SCIENTIST (Apr. 16, 2019), https://www.the-scientist.com/
news-opinion/two-patients-treated-with-crispred-cells-in-immunotherapy-trial-65744 
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subject, an adult man, was enrolled in November 2017, and no safety 
concerns appear to have emerged after enrollment of several more 
adult patient-subjects in this dose-escalation trial.105 However, the 
results have been disappointing,106 as is often the case the first time a 
new potential treatment is studied in human patient-subjects. 
Importantly, the experimental gene-editing intervention in this 
trial cannot cross the blood-brain barrier,107 so it cannot actually edit 
DNA in all the affected somatic cells. Because of the difficulty of 
reaching and effectively correcting all the affected cells in many 
genetic disorders, studying possible gene-editing treatments in 
affected patient-subjects is of great importance, but somatic cell gene 
editing in adults, and even in children, may not be as effective as 
interventions timed to prevent development of genetic disorders or to 
halt damage at an early stage. Treating an already-born person with 
somatic cell gene editing may not be perfectly effective if it is not 
possible to edit most or all of the affected DNA. If only some of the 
affected cells in the body are successfully edited, this results in 
mosaicism—a mosaic mixture of affected and corrected cells. 
Depending on the nature of the condition and the degree of 
correction, some mosaicism may be enough to effectively treat the 
condition, and in other cases, the effect may not be sufficient. In 
contrast, editing an early embryo can improve correction and avoid 
mosaicism, because the embryo has fewer cells needing correction, 
and all of the cells in an early embryo are rapidly dividing and can 
thus perpetuate the correction throughout development. Therefore, 
early intervention seems a logically superior route, as long as the risk 
of genetic disease is known. 
Once a couple has given birth to a child diagnosed with a genetic 
disorder, the child’s parents and their close relatives can learn more 
about their own relevant genetic makeup and can use various means 
 
[https://perma.cc/M53N-3NW2]. Both the treatment-oriented headline and the very 
preliminary public announcement about this research demonstrate current overexcitement 
about CRISPR’s potential. 
 105. Kaiser, supra note 104; Marilynn Marchione, Early Results Boost Hopes for 
Historic Gene Editing Attempt, ASSOCIATED PRESS (Sept. 5, 2018), 
https://www.apnews.com/2543a04b925c443b9ad3987f4209e68e [http://perma.cc/6MQY-YXAW]; 
Andrew McConaghie, No Safety Concerns So Far in Sangamo’s Groundbreaking Gene-
Editing Trial, PHARMAPHORUM (Feb. 7, 2018), https://pharmaphorum.com/news/no-safety-
concerns-far-sangamos-groundbreaking-gene-editing-trial/ [http://perma.cc/SW4U-RRAH]. 
 106. Ron Leuty, Why This East Bay Biotech Company Shed Half Its Value, S.F. BUS. 
TIMES (Feb. 7, 2019), https://www.bizjournals.com/sanfrancisco/news/2019/02/07/sangamo-
sgmo-genome-editing-mps-hurler-hunter.html [https://perma.cc/4C65-A3L7 (dark archive)]. 
 107. Kaiser, supra note 104. 
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to prevent the birth of additional affected children. Interestingly, 
current debates about germline gene editing tend to skip over 
discussion of some of those means. For example, long before the 
beginnings of the Human Genome Project, Ashkenazi Jewish 
communities worldwide began collating family histories to try to 
identify individuals whose offspring might be at risk of being affected 
by Tay-Sachs disease, a devastating neurodegenerative genetic 
disorder more common in persons with Ashkenazi Jewish ancestry 
than in the general population.108 Couples seeking to marry might be 
counseled to find another partner, to forgo procreation, or to adopt. 
As a result, the global incidence of Tay-Sachs disease has decreased 
substantially.109 Scientific advances have made even more options 
available to carrier couples, most notably including IVF to create a 
small number of embryos, PGD to test them for Tay-Sachs mutations, 
and selecting unaffected embryos to implant and bring to term.110 
Preventing germline transmission of genetic disease through the 
selection of healthy embryos is widely available in affluent countries. 
Assisted reproduction technology (“ART”) has expanded rapidly in 
recent decades, and IVF with PGD has become almost standard for 
those in need of reproductive health services, especially couples 
affected by genetic disorders who wish to give birth to a genetically 
related but unaffected child.111 However, IVF and PGD are relatively 
costly services, with prices ranging from four to six figures, depending 
on location and insurance coverage.112 In the United States, these 
procedures are largely the province of the private sector, are not 
comprehensively regulated, and are far from always paid for by 
 
 108. The Jewish Genetic Disease Consortium maintains a web resource on Tay-Sachs 
Disease that includes extensive information on the disorder, carrier screening for couples, 
and options for couples who screen positive. Tay-Sachs Disease, JEWISH GENETIC 
DISEASE CONSORTIUM, https://www.jewishgeneticdiseases.org/diseases/tay-sachs-disease/ 
[http://perma.cc/H3CW-X6W9]. 
 109. Marvin R. Natowicz & Elizabeth M. Prence, Heterozygote Screening for Tay-
Sachs Disease: Past Successes and Future Challenges, 8 CURRENT OPINION PEDIATRICS 
625, 627 (1996); Roberto Rozenberg & Lygia da Veiga Pereira, The Frequency of Tay-
Sachs Disease-Causing Mutations in the Brazilian Jewish Population Justifies a Carrier 
Screening Program, 119 SAO PAULO MED. J. 146, 146 (2001). 
 110. Learning About Tay-Sachs Disease, NAT’L HUM. GENOME RES. INST., 
https://www.genome.gov/10001220/learning-about-taysachs-disease/ [http://perma.cc/43S2-
H29Y]; see also Natowicz & Prence, supra note 109, at 626. 
 111. Robert Klitzman, How Much Is a Child Worth? Providers’ and Patients’ Views 
and Responses Concerning Ethical and Policy Challenges in Paying for ART, 12 PLOS 
ONE, e0171939, Feb. 16, 2017, at 1, 2. 
 112. Id. at 1–2. 
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private health insurance or included in government-funded health 
care. 
It is usually possible—not always, but almost always—to use IVF 
and PGD to select an unaffected embryo instead of editing an 
affected embryo. Regardless of whether the goal is to select an 
unaffected embryo or to edit one that is affected, it is necessary to use 
IVF to create one embryo or several, and then to use PGD to 
determine whether any are affected by the genetic disorder of 
concern (or are carriers). Selecting and implanting an unaffected 
embryo is thus a key alternative to editing an affected embryo. If 
editing an individual at a later stage—as an adult, a child, or even a 
fetus—is not enough, either because of mosaicism or because later 
editing cannot reverse early damage that occurs before the editing 
process is undertaken, then it might seem logical to regard embryo 
editing as nothing other than an alternative to embryo selection. The 
earlier the editing process begins in development, the more likely it is 
that all of the body’s cells will be corrected, including those of the 
(immature) gametes. This effectively makes germline editing a “side 
effect” of effective treatment. 
The gene-editing debate has thus reintroduced an important 
question113: If IVF and PGD are commonly used to select disease-free 
offspring, are there any good reasons to pursue gene editing of 
embryos (or of gametes114) aside from the rare instances when no 
unaffected embryo can be selected because all of a couple’s embryos 
will be affected? Most commentators have answered no;115 some have 
 
 113. Terence R. Flotte, Therapeutic Germ Line Alteration: Has CRISPR-Cas9 
Technology Forced the Question?, 26 HUM. GENE THERAPY 245, 245 (2015). 
 114. Hall, supra note 18; Regalado, Engineering the Perfect Baby, supra note 18, at 27–
30; see also George Church, Compelling Reasons for Repairing Human Germlines, 377 
NEW ENG. J. MED. 1909, 1910 (2017); Antonio Regalado, A New Way to Reproduce, MIT 
TECH. REV., Sept.–Oct. 2017, at 33, 35–38 [hereinafter Regalado, A New Way to 
Reproduce]. 
 115. See, e.g., Hampton, supra note 5, at 547–48; see also, e.g., Friedmann et al., supra 
note 61, at 1282; Elisabeth Hildt, Human Germline Interventions—Think First, 
FRONTIERS GENETICS, May 2016, at 1, 1–3; Lander, supra note 22, at 5–7; supra text 
accompanying notes 66–72 (addressing the National Academies of Science, Engineering, 
and Medicine’s cautious opposition to germline gene editing). In responding “no” to this 
question, numerous other scientists and bioethics scholars have condemned He Jiankui’s 
gene-editing experiments as both unnecessary and potentially dangerous. See supra notes 
86–99 and accompanying text. Further, Francis Collins, Director of the National Institutes 
of Health, added his censure in a strongly worded statement. Statement, Francis S. Collins, 
Dir., Nat’l Insts. of Health, Statement on Claim of First Gene-Edited Babies by Chinese 
Researcher (Nov. 28, 2018), https://www.nih.gov/about-nih/who-we-are/nih-director/
statements/statement-claim-first-gene-edited-babies-chinese-researcher [http://perma.cc/
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emphasized caution, without ruling out the future possibility;116 and a 
few have responded, “Of course; why not?”117 
Robust and reliable understanding of whether editing very early 
embryos or gametes can provide complete correction and target 
specificity is still in very short supply. Given our limited knowledge of 
the relationships among genes and between genes and the 
environment, genetic alteration of embryos or gametes might have 
completely unexpected consequences, which can be avoided simply 
by selecting an unaffected embryo. It thus seems only prudent to limit 
human clinical applications of gene editing to instances of true 
necessity, when an unaffected embryo cannot be selected. Recently, 
however, noted medical scientist George Daley has argued that many 
couples with low fertility may not be able to use IVF to create enough 
embryos to identify one that is unaffected to implant and bring to 
term.118 This could potentially expand the “necessary” application of 
embryo editing considerably.119 
But these are all safety questions. Some additional questions that 
should be asked may also highlight assumptions on which the whole 
field of ART is based. These questions touch on some potentially 
broader issues of social policy and ethics: Should every couple be able 
to pursue giving birth to children who are genetically related to both 
 
S28Y-QG4F]; see also Jon Cohen, Francis Collins Ponders Fallout from CRISPR Baby 
Study, SCIENCE (Nov. 30, 2018, 11:50 AM), https://www.sciencemag.org/news/2018/11/
epic-scientific-misadventure-nih-head-francis-collins-ponders-fallout-crispr-baby-study 
[http://perma.cc/Q3GG-UYW6]. 
 116. See, e.g., Dana Carroll, A Perspective on the State of Genome Editing, 24 
MOLECULAR THERAPY 412, 412–13 (2016); Flotte, supra note 113, at 245; Raheleh 
Heidari, David M. Shaw & Bernice Elger, CRISPR and the Rebirth of Synthetic Biology, 
23 SCI. ENGINEERING ETHICS 354, 355–57 (2016); Matthew H. Porteus & Christina T. 
Dann, Commentary, Genome Editing of the Germline: Broadening the Discussion, 23 
MOLECULAR THERAPY 980, 981–82 (2015); Jeremy Sugarman, Ethics and Germline Gene 
Editing, 16 EMBO REPS. 1, 1 (2015); Xiamoei Zhai, Vincent Ng & Reidar Lie, No Ethical 
Divide Between China and the West in Human Embryo Research, 16 DEVELOPING 
WORLD BIOETHICS 116, 117, 119 (2016). 
 117. See, e.g., Church, supra note 114, at 1910–11; Hall, supra note 18, at 57–58; Julian 
Savulescu et al., The Moral Imperative to Continue Gene Editing Research on Human 
Embryos, 7 PROTEIN CELL 476, 477 (2015); James Gallagher, Embryo Engineering a 
Moral Duty, Says Top Scientist, BBC NEWS (May 13, 2015), www.bbc.com/news/uk-
politics-32633510 [https://perma.cc/K5F5-DUBZ]; Pinker, supra note 17. Notably, George 
Church was the only scientist quoted as not condemning He Jiankui for his human 
genome-editing CRISPR experiment. See Marchione, supra note 86; Yong, supra note 89. 
 118. George Q. Daley, Robin Lovell-Badge & Julie Staffann, Perspective, After the 
Storm—A Responsible Path for Genome Editing, 380 NEW ENG. J. MED. 897, 898–99 
(2019). 
 119. Id. 
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parents? Should that effort overshadow adoption or the use of 
donated gametes? Should couples who have religious or personal 
objections to discarding any embryo be able to create only a single 
embryo, and correct it if needed, rather than creating more than one 
in order to identify and select one that is unaffected? 
And finally, and most central here, is it reasonable to regard the 
complexities and uncertainties of creating germline effects as 
acceptable side effects of embryo editing under the circumstances, in 
comparison to its potential benefits, even in instances of true need? 
How can germline effects be adequately studied in future generations 
from the perspectives of both science and ethics? How should 
genetically altered offspring be regarded? Are they lifelong research 
subjects? For how many generations?120 Could editing the germline 
alter the human genetic inheritance? What does that mean? Should 
we do so? What sort of policy process should be in place to address 
these questions? Is it possible to reach international agreement on 
whether to permit, and if so, how to regulate human germline 
alteration?121 
Although the germline effects of editing embryos, zygotes, or 
even gametes were initially posited as a side effect of effective 
treatment, it may ultimately be impossible to distinguish between 
germline alteration as a side effect and as a goal. If widespread use of 
IVF and PGD alone could remove most genetic diseases from the 
human genetic inheritance, then shouldn’t embryo editing be reserved 
for disorders that can be removed from the human genetic 
inheritance only by choosing not to procreate or by editing embryos 
or gametes? Perhaps because the same considerations and concerns 
exist about germline gene editing regardless of its status as side effect 
or goal, few efforts are made to preserve a distinction. Instead, most 
popular arguments in favor of embryo editing start and end with the 
goal of eradicating devastating genetic diseases forever.122 
 
 120. Friedmann et al., supra note 61, at 1282. 
 121. WALTERS & PALMER, supra note 27, at 90–91; Mark S. Frankel & Audrey R. 
Chapman, Facing Inheritable Genetic Modifications, 292 SCIENCE 1303, 1303 (2001); 
Juengst, supra note 21, at 15, 19; see discussion infra Section III.D. 
 122. Survey research very much depends on exactly how questions are asked, and to 
whom. See, e.g., CARY FUNK & MEG HEFFERON, PEW RESEARCH CTR., PUBLIC VIEWS 
OF GENE EDITING FOR BABIES DEPEND ON HOW IT WOULD BE USED 2–3 (2018). It is 
quite understandable that when people are asked about using gene editing to eliminate 
their own diseases from the population, they will find it easier to imagine themselves as 
healthy than to imagine that their parents selected an unaffected embryo instead of using 
gene editing on theirs. See Mullin, supra note 80. 
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When analysis of the ethical appropriateness of embryo editing 
equates editing with selection or fails to compare, consider, or even 
mention embryo selection, this increases the perceived acceptability 
of gene editing.123 It also helps to promote what some have argued is 
the real goal of embryo editing: genetic enhancement.124 Arguments 
in favor of genetic enhancement are further assisted by the 
conceptual fuzziness of the line between treatment and enhancement. 
B. Appropriate Research Targets: Treatment or Enhancement? 
Whether germline genetic alteration should be limited to 
treatment for genetic disorders or should encompass enhancements as 
well is yet another debate that has been going on for many decades.125 
Discussion of the similarities and differences among prevention, 
treatment, and enhancement is a debate that is older and broader 
than genetics, even though it has considerable significance in genetic 
intervention. Consider just two examples: vaccines enhance immune 
system function in order to prevent infection; erythropoetin is a 
treatment used to restore red blood cell production after cancer 
chemotherapy causes anemia, but it is also used to increase the 
blood’s oxygen-carrying capacity in order to prevent altitude sickness 
or enhance aerobic efficiency in healthy individuals. Many other such 
examples exist, including administering human growth hormone 
(“HGH”) as a treatment for children who have lower than normal 
HGH levels, while also giving HGH to uncomplicatedly short 
children with normal HGH levels to enhance the height they 
inherited from their parents. Many such “off label” uses of 
interventions developed as treatments have been proposed and 
undertaken in the history of medicine and medical research.126 
 
 123. See, e.g., Cohen, supra note 115. 
 124. See, e.g., Robert Sparrow, A Not-So-New Eugenics: Harris and Savulescu on 
Human Enhancement, HASTINGS CTR. REP., Jan.–Feb. 2011, at 32, 32–33; see also Eric T. 
Juengst et al., Is Enhancement the Price of Prevention in Human Genome Editing?, 1 
CRISPR J. 1, 1–2 (2018). 
 125. See WALTERS & PALMER, supra note 27, at 110–11. 
 126. The history of human gene-transfer research reveals numerous hopes for genetic 
enhancement, including but not limited to discussions about the feasibility of extending 
treatment uses of gene-transfer interventions to enhancement purposes. For example, 
could a gene-transfer intervention for cancer-caused cachexia be used to increase muscle 
mass in athletes (which, if done, would constitute difficult-to-detect “gene doping”)? 
Could delivering additional corrected copies of the mutated gene responsible for Prader-
Willi syndrome, a genetic disorder that includes insatiable appetite, to healthy overweight 
people suppress their appetites and result in weight loss? Might industry be interested in 
helping to develop a gene-transfer intervention to spur rapid regrowth of hair after 
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Examples like these demonstrate the difficulty of cleanly 
distinguishing between enhancement and treatment. The terms 
themselves are ambiguous and context dependent; treatment in one 
setting is enhancement in another. Moreover, as treatment 
interventions become more common, what is regarded as a condition 
in need of treatment is highly likely to expand into territory 
previously regarded as reserved for enhancement only, in the same 
way that the indications for use of an approved treatment virtually 
always expand over time.127 
Discussion of the ethical and policy debates about human 
enhancement, from everyday examples to the extremes of the anti-
aging movement and transhumanism, is far beyond the scope of this 
Article. Several aspects of genetic enhancement nonetheless deserve 
mention. 
First, assessing and balancing the risks of harm and potential 
benefits in enhancement research poses a particular challenge. It is far 
easier, and much less morally problematic, to weigh potential benefits 
and risks of harm in human research when the potential benefits are 
understood as a return to normal functioning—a treatment—than 
when the research subject is a healthy patient for whom “better than 
normal” is the goal. Despite this difficulty, biohackers have sought to 
enhance themselves.128 Enhancing human embryos should certainly 
be given far more serious consideration. 
But what if genetic enhancement is just at the far end of a 
continuum that represents the generally praiseworthy, or at least not 
automatically contemptible, desire to better ourselves? Humans 
 
chemotherapy so that it could also be used off-label for correction of male pattern 
baldness? All of these speculative possibilities have been discussed in meetings of the NIH 
Recombinant DNA Advisory Committee. 
 127. ERIC T. JUENGST & DANIEL MOSELEY, STANFORD ENCYCLOPEDIA OF 
PHILOSOPHY, HUMAN ENHANCEMENT 12 (Edward N. Zalta et al. eds., Spring 2016 ed. 
2016), https://plato.stanford.edu/entries/enhancement/ [https://perma.cc/7T6J-5FEX]; Juengst, 
supra note 21, at 21; Eric T. Juengst, Can Enhancement Be Distinguished from Prevention 
in Genetic Medicine?, 22 J. MED. & PHIL. 125, 126 (1997); Tristan Keys et al., Faith in 
Science: Professional and Public Discourse on Regenerative Medicine, in AFTER THE 
GENOME: A LANGUAGE FOR OUR BIOTECHNOLOGICAL FUTURE 11, 32–33 (Michael J. 
Hyde & James A. Herrick eds., 2013). 
 128. See, e.g., Josiah Zayner, The First Attempt at Human CRISPR Gene Editing, SCI., 
ART, BEAUTY (Oct. 13, 2017), http://www.josiahzayner.com/2017/10/the-first-human-to-
attempt-crispr-gene.html [https://perma.cc/8RM5-AXM6]; Sarah Zhang, A Biohacker 
Regrets Publicly Injecting Himself with CRISPR, ATLANTIC (Feb. 20, 2018), 
https://www.theatlantic.com/science/archive/2018/02/biohacking-stunts-crispr/553511/ 
[https://perma.cc/W86Z-VM2Z]. 
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already enhance themselves and their children in a wide variety of 
relatively modest ways: eyeglasses and laser surgery for myopia, 
education and Ritalin for academic achievement, meditation and even 
controlled administration of hallucinogens for moral enhancement, 
and caloric restriction for life extension. Inheritable genetic 
enhancements may hold the potential to change the balance of 
characteristics in a society more pervasively and permanently than 
other enhancement technologies currently available to individuals 
and families. Individual choices to ensure that one’s children and 
grandchildren are blond haired and blue-eyed, taller than average, 
more trusting and compassionate, possessing higher IQs, or needing 
less sleep potentially have a wide range of possible consequences 
across societies. Yet all parents seek to secure advantages for their 
children and pass them on across generations through the acquisition 
and inheritance of wealth, education, employment opportunities and 
experiences, contacts and connections, and other forms of social 
capital. Are genetic enhancements different in kind from other 
enhancements, or do they differ only in degree of precision, 
penetrance, and irreversibility? 
Many of the enhancements just described would not be regarded 
as advantageous if everyone had them. Being tall, or blond haired and 
blue-eyed, matters little if everyone is tall, or blond haired and blue-
eyed; these characteristics, and others that matter only if you have 
them and others do not, are, in economic or philosophical terms, 
positional goods.129 Some enhancements, in contrast, may continue to 
be desirable nevertheless, at least within limits. For example, more 
education or greater intelligence, more stamina, less need for sleep, 
and staying healthier longer may all confer advantages over 
individuals who lack these characteristics, but each enhancement may 
still have value if everyone shares them; they are, philosophically 
speaking, intrinsic goods.130 Even in circumstances where income-
related disparities will surely limit access to any and all genetic 
enhancements, whether for individuals alone or also for their 
progeny, it is worth considering what kinds of enhancements are even 
worthy of consideration in a society that seeks to be both free and 
fair. 
 
 129. FRED HIRSCH, THE SOCIAL LIMITS TO GROWTH 27 (rev. ed. 2005). 
 130. MICHAEL J. ZIMMERMAN, STANFORD ENCYCLOPEDIA OF PHILOSOPHY, 
INTRINSIC VS. EXTRINSIC VALUE 5–8 (Edward N. Zalta et al. eds., Spring 2015 ed. 2015), 
https://plato.stanford.edu/entries/value-intrinsic-extrinsic/ [https://perma.cc/VBG5-3PLY]. 
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Finally, even the most highly valued of intrinsic goods has a place 
on a continuum from enhancements that manipulate normal species 
functioning in minor ways, such as bringing short people up to the 
species norm or improving eyesight beyond 20/20 vision, to those that 
change normal species functioning more profoundly, such as tripling 
the human lifespan or enabling humans to photosynthesize in order to 
counter a shrinking food supply on an overheating planet. Inheritable 
genetic modifications, now potentially made much easier by gene 
editing, may be difficult to undo. Thus, even if genetic enhancement is 
currently no more than a philosopher’s dream, contemplating the 
inheritable changes that could in the future be wrought by human 
germline gene editing may add at least a modicum of urgency to 
ongoing ethical and policy deliberations about human enhancement. 
We need to worry about this because it simply may not be possible to 
avoid embryo enhancement if embryo editing goes forward. 
C. Oversight and Governance, Domestic and Global 
That gene editing provides an unparalleled opportunity to 
address significant questions about governance of new technologies, 
appropriate oversight, and issues of justice, both domestic and global, 
seems an understatement. That we are very far from being able to 
capitalize on that opportunity seems equally obvious. The reasons are 
legion: international scientific competition, a proliferation of 
regulatory and oversight mechanisms replete with gaps and overlaps, 
historical precedents like the “Wild West” of ART in the United 
States, and the accessibility and affordability of do-it-yourself 
CRISPR kits for at-home biohacking are just a few of the 
contributors to the patchwork picture.131 
 
 131. See generally Marianne J. Legato et al., Editing the Human Genome: Progress and 
Controversies, 1 GENDER & GENOME 4, 5–7 (2016) (recounting a roundtable discussion 
on the progress of human gene editing and the reasons it is controversial). In addition, the 
European Union’s recent determination that gene-edited organisms should be regarded as 
genetically modified organisms from a regulatory standpoint has added confusion and 
consternation to the mix. See Press Release, Court of Justice of the European Union, 
Organisms Obtained by Mutagenesis Are GMOs and Are, in Principle, Subject to the 
Obligations Laid Down by the GMO Directive (July 25, 2018), https://curia.europa.eu/
jcms/upload/docs/application/pdf/2018-07/cp180111en.pdf [https://perma.cc/72JD-GHPN]. 
Finally, organisms obtained by mutagenesis qualify as genetically modified and are 
therefore subject to the GMO Directive’s obligations. Id.; see also Rodolphe Barrangou, 
CRISPR Craziness: A Response to the EU Court Ruling, 1 CRISPR J. 251, 251 (2018); 
Press Release, Court of Justice of the European Union, supra. One important, agreed-
upon but largely nonregulatory limitation on human embryo research—the so-called 
fourteen-day rule—is applied widely but differently across national boundaries and plays a 
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To address this kind of complexity, which is not at all 
unprecedented, Marchant and Wallace have suggested applying a 
model called a “governance coordinating committee,” which can 
make use of a “soft law” approach to novel biotechnologies by 
serving a managerial “honest broker” function.132 Is there a path 
forward for establishing a governance coordination committee for 
gene editing? Well, the summary statement from the organizers of the 
Second International Summit on Human Genome Editing 
calls for an ongoing international forum to foster broad public 
dialogue, develop strategies for increasing equitable access to 
meet the needs of underserved populations, speed the 
development of regulatory science, provide a clearinghouse for 
information about governance options, contribute to the 
development of common regulatory standards, and enhance 
coordination of research and clinical applications through an 
international registry of planned and ongoing experiments.133 
In addition, consider that the NIH has recently decided to yet 
again revise and reduce the role of the Recombinant DNA Advisory 
Committee (“RAC”) in the oversight of human gene-transfer 
research, having concluded that gene-transfer research no longer 
needs the scrutiny that should be afforded to novel biotechnologies. 
As part of this revision, “to use the RAC as a public forum to advise 
on issues associated with emerging biotechnologies, the RAC’s 
charter will be modified to change the committee’s focus from 
 
fundamental role in gene editing and related research. Insoo Hyun, Amy Wilkerson & 
Josephine Johnston, Human-Embryo Research: Revisit the 14-Day Rule, 533 NATURE 169, 
170 (2016). 
 132. Marchant & Wallach, supra note 13, at 46, 48 (“Emerging technologies require a 
coordinated, holistic, and nimble approach, while not sacrificing diligence in overseeing 
discernible dangers. .	.	. It would be an illusion to think that a GCC, or any other body, 
could resolve these problems altogether. However, through advice, influence, and building 
rapport among stakeholders, a GCC could play a key role in modulating the development 
and deployment of new technologies. Today, no single institution is positioned to play 
such a role.”). 
 133. Statement, Organizing Comm. of the Second Int’l Summit on Human Genome 
Editing, On Human Genome Editing II (Nov. 29, 2018) [hereinafter Organizing 
Committee Statement], http://www8.nationalacademies.org/onpinews/newsitem.aspx?	
RecordID=11282018b [https://perma.cc/7WU2-DB2R]; see also Statement, Marcia 
McNutt, President, Nat’l Acad. of Scis., and Victor J. Dzau, President, Nat’l Acad. of 
Med., Statement on the Second International Summit on Human Genome Editing (Nov. 
29, 2018) [hereinafter Presidents’ Statement], http://www8.nationalacademies.org/
onpinews/newsitem.aspx?RecordID=11282018c [https://perma.cc/DD25-95HH]. 
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research solely involving recombinant or synthetic nucleic acids to 
emerging biotechnologies research.”134 
If the RAC is actually reformulated to provide a public forum 
that can advise broadly on scientific, safety, and ethical issues arising 
in research on emerging biotechnologies, perhaps there is some hope 
that it could continue to listen, deliberate, and influence the progress 
of gene-editing research and related biotechnologies. That would be 
desirable. It remains to be seen whether the NIH truly intends to 
make this change; however, its director, Francis Collins, has 
referenced it in his response to the He Jiankui scandal.135 It is far from 
clear at the time of this writing what this model could really 
accomplish.136 Even so, another proponent of responsible research 
progress instead of moratoria in this socially and politically sensitive 
area has also called for a comprehensive regulatory roadmap that 
would incorporate a wide variety of guidelines, controls, and 
checkpoints.137 
D. A Moratorium? 
Notably, in mid-March an international group of genome 
scientists and bioethics scholars published an article in Nature calling 
for a moratorium on “heritable genome editing.”138 An accompanying 
editorial echoed the need for better regulation and broader 
discussion,139 and the same issue published letters from NIH and the 
National Academies supporting a moratorium.140 
The moratorium call is detailed, addressing the need to improve 
the efficiency of IVF and PGD as potentially preferable to clinical 
genome editing, endorsing the continuation of basic genome-editing 
 
 134. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid 
Molecules, 83 Fed. Reg. 41,082, 41,083 (Aug. 17, 2018); see also Francis S. Collins & Scott 
Gottlieb, The Next Phase of Human Gene-Therapy Oversight, 379 NEW ENG. J. MED. 
1393, 1395 (2018) (“The NIH envisions using the RAC as an advisory board on today’s 
emerging biotechnologies, such as gene editing, synthetic biology, and neurotechnology, 
while harnessing the attributes that have long ensured its transparency.”). 
 135. See Cohen, supra note 115; see also Organizing Committee Statement, supra note 
133; Presidents’ Statement, supra note 133. 
 136. Nancy M. P. King, RAC Oversight of Gene Transfer Research: A Model Worth 
Extending?, 30 J.L. MED. & ETHICS 381, 386 (2002). 
 137. R. Alta Charo, Rogues and Regulations of Germline Editing, 380 NEW ENG. J. 
MED. 976, 976 (2019). 
 138. Eric Lander et al., Adopt a Moratorium on Heritable Genome Editing, 567 
NATURE 165, 165–68 (2019). 
 139. Editorial, Set Rules for Genome Editing, 567 NATURE 145, 145 (2019). 
 140. Correspondence, 567 NATURE 175, 175 (2019). 
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research, and positing the global moratorium on clinical genome 
editing as voluntary and temporary. Not surprisingly, however, it was 
immediately controversial, with prominent scientists and scholars 
supporting both sides of the question for a wide range of reasons.141 
As at least two international expert groups,142 with some members 
already clearly in both “slow down” and “move ahead” camps, have 
pledged to work together to define terms, discuss scientific and ethical 
issues, and set standards in germline genome-editing research, the 
controversy over global governance and research policy is sure to 
remain significant. 
E. Access and Cost 
Cost and access have been important concerns for all treatment 
technologies for as long as paying for health care has been an issue. 
Both domestically and on a global scale, new biotechnologies often 
come with immense price tags. 143  Gene-transfer, cell-based, and 
regenerative-medicine interventions are, generally speaking, very 
expensive; some efforts are being made to reduce costs through scale-
up and standardization,144 but the success of such efforts is uncertain. 
 
 141. Jon Cohen, New Call to Ban Gene-Edited Babies Divides Biologists, SCIENCE 
(Mar. 13, 2019, 2:00 PM), https://www.sciencemag.org/news/2019/03/new-call-ban-gene-
edited-babies-divides-biologists [https://perma.cc/9KSX-XJLA]. And on April 24, in a 
letter sent to Alex Azar, United States Secretary of Health and Human Services, sixty-two 
scientists and bioethics scholars strongly supported a moratorium. See Gene Therapy 
Leaders Urge Global Moratorium on Germline Editing, GENETIC ENGINEERING & 
BIOTECHNOLOGY NEWS (Apr. 24, 2019), https://www.genengnews.com/topics/genome-
editing/gene-therapy-leaders-urge-global-moratorium-on-germline-editing/ [https://perma.cc/
E9VA-ZS96]. 
 142. There is a new WHO expert advisory committee to develop governance and 
oversight standards for human genome editing. WHO Expert Advisory Committee on 
Developing Global Standards for Governance and Oversight of Human Genome Editing, 
WORLD HEALTH ORG., https://www.who.int/ethics/topics/human-genome-editing/
committee-members/en/ [https://perma.cc/J3FD-CUX8]. There is also an international 
commission, formed by the National Academies of Science and Medicine and the United 
Kingdom Royal Society. See Correspondence, supra note 140, at 175. 
 143. E.g., Nancy M. P. King & Christine E. Bishop, New Treatments for Serious 
Conditions: Ethical Implications, 24 GENE THERAPY 534, 536 (2017); Damien Garde, The 
Cure for ‘Bubble Boy’ Disease Will Cost $665,000, STAT (Aug. 3, 2016), 
https://www.statnews.com/2016/08/03/gene-therapy-price-gsk/ [https://perma.cc/L8EX-6PKS]; 
Meghana Keshavan, We May Soon Have Our First $1 Million Drug. Who Will Pay for It? 
And How?, STAT (Oct. 13, 2017), https://www.statnews.com/2017/10/13/gene-therapy-
pricing/?utm [https://perma.cc/T5JF-QFCH]. 
 144. Joshua G. Hunsberger, Thomas Shupe & Anthony Atala, An Industry-Driven 
Roadmap for Manufacturing in Regenerative Medicine, 7 STEM CELLS TRANSLATIONAL 
MED. 564, 564–68 (2018). 
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It is possible that the speed and simplicity of CRISPR-Cas9 and 
other gene-editing tools may help to reduce gene editing’s ultimate 
cost. Even significant cost reductions will not necessarily improve the 
affordability of future treatments, however, particularly for patients 
in resource-poor countries, unless gene editing proves far more 
curative and considerably cheaper than currently available 
treatments, thus making it feasible to ensure global accessibility. 
Countries that cannot afford to provide basic health care for the 
people residing within their borders are unlikely to provide novel 
biotechnologies, even at low cost. Countries that—like the United 
States—choose to condition access to health care on the ability to pay 
for it, with exceptions for only some of those with the least resources 
and the greatest need, are unlikely to remove or lower that barrier for 
particular new technologies, no matter how promising. 
This is only to say that the cost problem in health care is 
pervasive; gene editing will simply be another new and expensive 
biotechnology. But because gene editing of embryos must necessarily 
be integrated into existing ART systems, which are already financially 
out of reach for many, disparities of access will surely be exacerbated 
unless our thinking about payment for such services changes 
profoundly. 
And yet, it must be acknowledged that the issue of fair access to 
costly biotechnologies is a question of distributive justice that is 
confined to the rather small and circumscribed realm of rescue 
medicine. There are other, much broader distributive justice 
questions that should also be considered. We should ask: How should 
we distribute not only fair access to novel biotechnological treatments 
but also to preventive services and also to the support services that 
are often so necessary when treatments are not cures? How should we 
fairly apportion funding for health-related research between the 
development of novel biotechnologies and the search for effective 
prevention? Should we focus instead on identifying, addressing, and 
ameliorating the many social factors that give rise to health disparities 
but that have proven more challenging—and much less exciting—
than pursuing cutting-edge science? 145  Should we even consider 
thinking beyond health, to engage more seriously in collective 
discussion about all the things that make up a good life, and about 
 
 145. REBECCA DRESSER, WHEN SCIENCE OFFERS SALVATION 47 (2001). 
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what societies should do to make the lives of the people who live in 
them better?146 
IV.  CAN POLICY SHAPE SCIENCE? 
Somatic cell gene editing is not new, although CRISPR-Cas9, its 
relatives, and the recent development of even newer and potentially 
more precise techniques, like base editing, have made it far easier. 
However, the editing of early embryos and gametes is necessarily 
controversial. There is still agreement that clinical research involving 
human embryos intended for reproduction must wait until much more 
is known, but calls for complete avoidance of germline gene editing 
are increasingly in the minority. 
A. Is Germline Editing the Future? 
The question whether deliberate germline gene editing should 
ever be permitted is a question about the nature of the need. IVF 
combined with PGD is a safe and effective already-existing 
alternative to gene editing of embryos or gametes in all but the few 
circumstances where a genetic disorder will necessarily appear in all 
of the embryos a couple can produce. Yet there are would-be parents 
who might prefer editing a single embryo over creating and testing 
multiple embryos, selecting and implanting one or two unaffected 
embryos, and discarding the rest.147 And there are other would-be 
parents with a range of different reasons for seeking gene editing.148 
 
 146. Juengst, supra note 21, at 19. See generally MADISON POWERS & RUTH FADEN, 
SOCIAL JUSTICE: THE MORAL FOUNDATIONS OF PUBLIC HEALTH AND HEALTH POLICY 
(2008) (proposing that health is only one of six essential dimensions of well-being to which 
all people deserve access). 
 147. Nonetheless, what philosophers refer to as the “nonidentity problem”—that is, 
that selecting an unaffected embryo means choosing a different potential person, whereas 
editing an embryo means treating the same potential person—may be a distinction that is 
more illusory than meaningful. Interview with Janet Malek, Assoc. Professor, Baylor Coll. 
of Med. (Oct. 19, 2018). 
 148. See Daley et al., supra note 118, at 897–99 (addressing the needs of couples with 
low fertility). For instance, there are would-be fathers with genetic disorders who would 
choose to have their spermatogonial stem cells genetically altered and reimplanted into 
their testes so that they can reproduce “naturally.” See Church, supra note 114, at 1909–11. 
And there are same-sex couples who would choose to create bipaternal or bimaternal 
embryos, should that technology become available. See Zhi-Kun Li et al., Generation of 
Bimaternal and Bipaternal Mice from Hypomethylated ESCs with Imprinting Region 
Deletions, 23 CELL STEM CELL 665, 665 (2018). It is noteworthy that the He Jiankui 
scandal has not deterred some researchers from studying similar preventive interventions. 
See Antonio Regalado, Despite CRISPR Baby Controversy, Harvard University Will Begin 
Gene-Editing Sperm, MIT TECH. REV. (Nov. 29, 2018), https://www.technologyreview.com/
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When editing, rather than selection, is chosen or necessary, 
germline alteration is then a side effect of editing embryos, zygotes, or 
gametes in order to ensure that the intervention is completely 
effective with little or no possibility of mosaicism. But affecting the 
germline is also a goal in itself, accomplished by either embryo 
selection or embryo editing. IVF, PGD, and embryo selection already 
work to eliminate deleterious conditions from the human germline, 
without gene editing’s uncertain and unknown effects on future 
generations. Yet there is no groundswell of enthusiasm for making 
these standard technologies more widely available. The scientific 
excitement that accompanies genetic manipulation risks 
overwhelming the ability of professionals and the public to place 
these novel biotechnologies in perspective.149 
As a result, it is highly likely that over time, more and more 
embryo editing could come to be regarded as necessary, along with its 
germline effects, whether inadvertent or desired. And only editing 
can create (and perpetuate) enhancements. 
B. Is Enhancement Inevitable? 
The prospect of genetic enhancement is far more feasible with 
gene editing than it has ever been with gene addition. The simple 
existence of the technology has given rise to an imaginative fervor 
that so far has outpaced serious discussion about what enhancement 
means and what its consequences might be—despite the greatly 
expanded problems of assessing safety and even of predicting the 
meaning of efficacy when enhancement rather than correction is at 
issue.150 
 
s/612494/despite-crispr-baby-controversy-harvard-university-will-begin-gene-editing-sperm/ 
[https://perma.cc/2KEA-CXFW]. 
 149. There are undoubtedly ambitious scientists and entrepreneurs who are inspired 
rather than deterred by Dr. He’s experience. See Antonio Regalado, The DIY Designer 
Baby Project Funded with Bitcoin, MIT TECH. REV. (Feb. 1, 2019), 
https://www.technologyreview.com/s/612838/the-transhumanist-diy-designer-baby-funded-
with-bitcoin/ [https://perma.cc/S4FV-WUMQ]. And though beyond the scope of this 
Article, editing gametes is definitely regarded by the scientific community as a viable 
strategy to be studied, and one highly reputable scientist, George Daley, Dean of Harvard 
Medical School, supports continuing research looking toward clinical applications, even 
after Dr. He. See Regalado, A New Way to Reproduce, supra note 114, at 35. 
 150. The regulatory requirements for research with human subjects require a 
reasonable balance between risks of harm and potential benefits. But as discussion of Dr. 
He’s research demonstrates, when seeking to enhance a healthy human, it is at best 
somewhat challenging to assess the potential benefits of making someone “better than 
normal” and compare those elusive benefits to the risks of harm. See Rebecca Dresser, 
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Addressing the problem of unequal access to costly 
biotechnologies barely dents the ethical issues raised by this 
challenging future possibility. Gene editing represents a major 
scientific leap forward, rekindling public excitement about the 
possibility of significant amelioration of genetic disorders in the 
foreseeable future. Yes, it will take quite some time before many 
human clinical gene-editing trials using CRISPR-Cas9 are underway, 
but clinical translation seems likely to move more quickly than it has 
for other novel biotechnologies. After all, research in healthy human 
embryos was approved in two countries just a year after the first 
publication of gene-editing research in tripronuclear human embryos 
in China.151 And the controversy over He Jiankui’s work is likely to 
continue for some time.152 
C. Sticking to the Basics: A Proposal 
Despite the push toward clinical applications of human embryo 
editing, it matters a great deal whether the translational pathway is 
expected to follow a straight line or not. It seems likely that genetic-
modification research in human embryos will continue and expand, 
but basic and proof-of-principle research may be far more vital than 
speeding toward the clinic. Gene-editing research using human 
embryos to gain basic knowledge of embryonic development and 
infertility is currently underway. Researchers received approval early 
in 2016 to use CRISPR-Cas9 in healthy donated embryos in the 
United Kingdom and in Sweden; by September, National Public 
Radio announced that the Swedish team had started their work.153 
 
Genetic Modification of Preimplantation Embryos: Toward Adequate Human Research 
Policies, 82 MILBANK Q. 195, 207, 209 (2004); Yong, supra note 89. 
 151. See Michelle Taylor, Japan Joins List of Countries that Allow Gene Editing in 
Human Embryos, LABORATORY EQUIPMENT (Oct. 5, 2018, 2:06 PM), 
https://www.laboratoryequipment.com/news/2018/10/japan-joins-list-countries-allow-gene-
editing-human-embryos [https://perma.cc/Z8HM-YURE]. 
 152. In recent news identified for this Article, Dr. He continued to defend his research 
and stated that he was seeking publication of his data. Luke W. Vrotsos, Chinese 
Researcher Who Said He Gene-Edited Babies Breaks Week of Silence, Vows to Defend 
Work, HARV. CRIMSON (Dec. 7, 2018), https://www.thecrimson.com/article/2018/12/
7/harvard-profs-react-to-human-gene-edit/ [https://perma.cc/7XMC-XG9R]. But cf. Henry 
T. Greely, He Jiankui, Embryo Editing, CCR5, the London Patient, and Jumping to 
Conclusions, STAT (Apr. 15, 2019), https://www.statnews.com/2019/04/15/jiankui-embryo-
editing-ccr5/ [https://perma.cc/QE3G-KKQS] (“Not only was He ethically wrong in doing 
this work, but its scientific basis was even weaker than generally recognized.”). 
 153. Ewen Callaway, Embryo Editing Gets Green Light, 530 NATURE 18, 18 (2016); 
Ewen Callaway, Embryo-Editing Research Gathers Momentum, 532 NATURE 289, 289 
(2016); Park, supra note 11, at 45; Rob Stein, Breaking Taboo, Swedish Scientist Seeks to 
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Since then, researchers in the United Kingdom and elsewhere have 
made significant contributions to basic knowledge of embryo 
development and disease modeling. 154  Recently, an expert panel 
convened by the Japanese Ministry of Education, Culture, Sports, 
Science, and Technology drafted guidelines recommending gene 
editing of human embryos for basic science research. 155  And a 
developmental biologist in the United States is using CRISPR to test 
the efficacy of editing deleterious mutations like retinitis pigmentosa 
out of human embryos in very early stages of development.156 
Although basic embryo research using CRISPR might seem like 
nothing other than the first step on the pathway of clinical translation, 
it should instead be considered a goal in itself. CRISPR was 
discovered and developed because scientific curiosity led to scientific 
excitement about the ability to understand, refine, and manipulate a 
newly identified biological ability. The basic embryo research that 
CRISPR makes possible seeks to improve scientific understanding of 
human growth and development in ways that may not lead directly to 
clinical applications but that may have far greater capacity to improve 
the health of many in the long run. Renewed attention to basic 
principles of careful and deliberate knowledge-generating research 
can do a lot to slow the race to the clinic and help to ensure that what 
ultimately succeeds in moving from “bench to bedside” is safe and 
effective, because more is known about how and why it works.157 
 
Edit DNA of Healthy Human Embryos, NPR (Sept. 22, 2016, 5:07 AM), 
http://www.npr.org/sections/health-shots/2016/09/22/494591738/breaking-taboo-swedish-
scientist-seeks-to-edit-dna-of-healthy-human-embryos [https://perma.cc/7T6J-5FEX]. 
 154. See, e.g., Norah M. E. Fogarty et al., Genome Editing Reveals a Role for OCT4 in 
Human Embryogenesis, 550 NATURE 67, 67 (2017); Heidi Ledford, CRISPR Used to Peer 
into Human Embryos’ First Days, NATURE (Sept. 20, 2017), https://www.nature.com/
news/crispr-used-to-peer-into-human-embryos-first-days-1.22646 [https://perma.cc/EU5K-
J5GN]. 
 155. David Cyranoski, Japan Set to Allow Gene Editing in Human Embryos, NATURE 
(Oct. 3, 2018), https://www.nature.com/articles/d41586-018-06847-7 [https://perma.cc/
FXG4-ZTST]. 
 156. Rob Stein, New U.S. Experiments Aim to Create Gene-Edited Human Embryos, 
NPR (Feb. 1, 2019, 5:42 PM), https://www.npr.org/2019/02/01/690822745/u-s-scientists-
researching-gene-editing-in-human-embryos [https://perma.cc/XJ75-3Z5F]. 
 157. JONATHAN KIMMELMAN, GENE TRANSFER AND THE ETHICS OF FIRST-IN-
HUMAN RESEARCH: LOST IN TRANSLATION 111 (2009); Steven Joffe & Franklin G. 
Miller, Bench to Bedside: Mapping the Moral Terrain of Clinical Research, HASTINGS CTR. 
REP., Mar.–Apr. 2008, at 30, 32, 36. It is noteworthy that the authors of the call for a 
moratorium on clinical germline editing have taken this position. See Lander et al., supra 
note 138, at 166 (“To be clear, our proposed moratorium does not apply to germline 
editing for research uses, provided that these studies do not involve the transfer of an 
embryo to a person’s uterus.”). 
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It is also important to recognize that the tremendous—and 
justified—scientific excitement about CRISPR and related gene-
editing tools may ultimately result in only modest clinical benefit, 
precisely because the knowledge gains from basic and preclinical 
research are themselves broadly generalizable rather than targeted to 
treatment breakthroughs. This is the way all science generally works, 
and despite the rapid translation of scientific excitement about gene 
editing into the popular press, the science of gene editing works this 
way too. 
Great clinical breakthroughs could indeed come from CRISPR; 
only time will tell. But progress is truly more likely if its pace is slow 
and steady and if detours and switchbacks are encouraged as learning 
opportunities. It may be too late to temper public expectations or 
broaden public deliberation about gene editing, but reinforcing 
scientific responsibility is a duty borne by all those who think about 
the relationship of science to society. When shared governance is 
nearly impossible to achieve or even conceive of in a global explosion 
of scientific excitement and increasingly accessible technology, 
sharing conversation plays a vital role in supporting and perpetuating 
a global commitment to harm prevention, practical wisdom, and 
reasoned reflection about medical progress. 
One of the most important outcomes of the “gene-edited babies” 
controversy should be renewed attention to the relationship between 
good science and the ethical and social value of responsible scientific 
progress. Whether or not He Jiankui is appropriately characterized as 
a rogue scientist, many researchers and scholars have noted that 
ethically sound research means more than simple adherence to laws 
and regulations. Some have gone on to point out that critical 
reflection about the ethical underpinnings of human research and the 
promotion of open and robust discussion regardless of self-interest 
are essential.158 After all, Dr. He appears to believe that his work is 
 
 158. See, e.g., J. Benjamin Hurlbut & Jason Scott Robert, CRISPR Babies Raise an 
Uncomfortable Reality—Abiding by Scientific Standards Doesn’t Guarantee Ethical 
Research, CONVERSATION (Dec. 3, 2018, 6:33 AM), https://theconversation.com/crispr-
babies-raise-an-uncomfortable-reality-abiding-by-scientific-standards-doesnt-guarantee-
ethical-research-108008 [https://perma.cc/9B3K-RWUR]; Mark Yarborough, Who Missed 
the Chance to Stop the CRISPR Babies Scientist? Look in the Mirror, STAT (Nov. 30, 
2018), https://www.statnews.com/2018/11/30/missed-chance-stop-crispr-babies-scientist/ 
[https://perma.cc/74M9-YR2E]; see also Jon Cohen, Stanford Says Its Researchers Did Not 
Help Chinese Biologist Who Gene Edited Babies, SCIENCE (Apr. 16, 2019), 
https://www.sciencemag.org/news/2019/04/stanford-says-its-researchers-did-not-help-chinese-
biologist-who-gene-edited-babies [https://perma.cc/9A43-35B4]. 
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both ethical and necessary; the extent to which he may have 
misunderstood what seems clear to others is a cautionary commentary 
on ethics education in the sciences, at every level.159 The integrity of 
scientific data and the ethics of translational research are 
interdependent.160 Both depend upon public and policy conversations 
about what constitute common human values and why we hold 
them. 161  This is why careful, transparent attention to all its 
implications is essential to the success of all new science. As difficult 
and all consuming as that attention is, both for scientists and for the 
rest of society, the promise of gene editing deserves no less. 
CONCLUSION 
This Article has attempted, in a drastically condensed discussion, 
to describe the rapid development of gene editing and to highlight the 
scientific, medical, ethical, and policy challenges posed by editing the 
genomes of embryos destined to be born. Such edits are expected to 
be inherited by future generations. Although developing effective 
genetic treatments for already-born persons is universally desirable, 
inheritable genetic changes have been prohibited or, at best, regarded 
with extreme caution, for a variety of ethical, policy, and scientific 
reasons, including concern about the high likelihood of dangerous 
outcomes, desire to make use of less drastic means of eliminating 
genetic disease, and the hope of preserving the human genetic 
inheritance without introducing uncontrolled enhancements. 
Careful and thoughtful ongoing research can make use of 
CRISPR and related editing technologies in order to learn more 
about human development and disease, and thus has a promising 
 
 159. See, e.g., Sharon Begley, He Took a Crash Course in Bioethics. Then He Created 
CRISPR Babies, STAT (Nov. 27, 2018), https://www.statnews.com/2018/11/27/crispr-
babies-creator-soaked-up-bioethics/ [https://perma.cc/TP6F-RBEP]; Jon Cohen, After Last 
Week’s Shock, Scientists Scramble to Prevent More Gene-Edited Babies, SCIENCE (Dec. 4, 
2018, 5:25 AM), https://www.sciencemag.org/news/2018/12/after-last-weeks-shock-scientists-
scramble-prevent-more-gene-edited-babies [https://perma.cc/99SY-ZWE9]; Vrotsos, supra 
note 152. Notably, Dr. He and several coauthors, including an American public relations 
specialist, authored an article in 2018 entitled “Draft Ethical Principles for Therapeutic 
Assisted Reproductive Technologies.” See Retraction of: Draft Ethical Principles for 
Therapeutic Assisted Reproductive Technologies by He J et al., CRISPR J 2018; Fast Track. 
DOI:10.1089/crispr/2018/0051, 2 CRISPR J. 65, 65 (2019). This document, the content of 
which is questionable in many ways, was published online by the CRISPR Journal before 
the news about the twins became public. Id. It never made it into the relevant issue of the 
journal, online or in print, and has since been taken down entirely. Id. 
 160. KIMMELMAN, supra note 157, at 94–95; Joffe & Miller, supra note 157, at 32. 
 161. See, e.g., DRESSER, supra note 145, at 116–17. 
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future. However, the desire to develop inheritable genetic 
modifications—including enhancements—is surprisingly strong, as He 
Jiankui’s work has demonstrated. Moreover, Dr. He’s work has 
shown that even if there were clear and universal agreement, there is 
no global enforcement mechanism able to detect deviations 
prospectively. Much depends upon continuing, clear, and complete 
discussion among scientists, bioethics scholars, and policymakers 
worldwide. Much also depends upon robust ethics education for 
scientists as well as for the public. But the real question is whether, 
after Dr. He, the genie can be put back in the bottle. Only time will 
tell. 
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